{"gene":"SCD","run_date":"2026-06-10T07:46:29","timeline":{"discoveries":[{"year":1995,"finding":"SCD1 is the key rate-limiting enzyme that catalyzes the biosynthesis of monounsaturated fatty acids (MUFAs) from saturated fatty acids, playing a central role in fat cell metabolism and de novo lipogenesis. Its expression is regulated by dietary and hormonal signals.","method":"Review of biochemical and molecular studies on SCD gene family","journal":"Progress in lipid research","confidence":"High","confidence_rationale":"Tier 1 / Strong — foundational enzymatic characterization replicated across multiple studies, established as rate-limiting desaturase activity","pmids":["7480063"],"is_preprint":false},{"year":2017,"finding":"Oleate (an SCD1 product) specifically activates SREBP-1 nuclear accumulation and restores SREBP-1 expression and de novo lipogenesis in SCD1-deficient hepatocytes. SCD1 deficiency increases polyunsaturated fatty acid content, which in turn drives increased β-oxidation. These effects were demonstrated using Scd1-deficient mice and transgenic mice with liver-specific oleate or palmitoleate production.","method":"Scd1-deficient mice, transgenic mice (GLS5, GLS3), hepatocyte culture, SREBP-1 nuclear accumulation assay, gene expression analysis","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic mouse models with orthogonal methods, direct mechanistic link between SCD1 product oleate and SREBP-1 signaling established","pmids":["28851735"],"is_preprint":false},{"year":2019,"finding":"SCD1 deficiency in skeletal muscle activates AMPK through an increase in AMP levels, while muscle-specific SCD1 overexpression decreases AMPK phosphorylation and the AMP/ATP ratio. AMPK changes caused by SCD1 modulation affect NAD+ levels and consequently SIRT1 activity and histone H3K9 acetylation/methylation status.","method":"SCD1 knockout mice, muscle-specific SCD1 overexpression mice, pharmacological SCD1 inhibition, measurement of AMP/ATP ratio, AMPK phosphorylation, NAD+ levels, SIRT1 activity, histone modification","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain- and loss-of-function in vivo models with multiple orthogonal metabolic readouts establishing SCD1→AMP/ATP→AMPK→SIRT1→histone acetylation axis","pmids":["31241768"],"is_preprint":false},{"year":2019,"finding":"MITF is a lineage-restricted transcriptional activator of SCD (stearoyl-CoA desaturase) in melanoma. SCD is required for MITFHigh melanoma cell proliferation, and the MITF-SCD axis suppresses metastasis and inflammatory signaling. MITFLow cells are insensitive to SCD inhibition, demonstrating cell phenotype-dependent effects.","method":"Genetic SCD inhibition/knockdown in melanoma cells, MITF modulation, proliferation and invasion assays, in vivo metastasis models, transcriptional reporter assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacological loss-of-function with multiple orthogonal phenotypic readouts, lineage-restriction established through comparative cell models","pmids":["31733993"],"is_preprint":false},{"year":2020,"finding":"Lactate uptake via MCT1 promotes ATP production in hepatocellular carcinoma cells, deactivating AMPK, leading to upregulation of SREBP1 and downstream SCD1, thereby enhancing production of anti-ferroptotic monounsaturated fatty acids and conferring resistance to ferroptosis inducers RSL3 and Erastin.","method":"MCT1 inhibition/genetic knockdown, AMPK activation/inhibition, SREBP1 and SCD1 modulation, ferroptosis assays in vitro and in vivo xenograft models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic and pharmacological interventions at each step of the pathway with in vitro and in vivo validation","pmids":["33296645"],"is_preprint":false},{"year":2020,"finding":"FBW7 inhibits the expression of SCD1 via inhibiting the transcription factor NR4A1 (nuclear receptor subfamily 4 group A member 1), thereby promoting ferroptosis and apoptosis in pancreatic cancer cells.","method":"Gene expression profiling, targeted metabolite analysis, genetic FBW7 overexpression/knockdown, NR4A1 and SCD1 modulation, lipid peroxidation assays","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, mechanistic axis established by genetic manipulation but without direct promoter or binding studies for FBW7-NR4A1-SCD1","pmids":["33271455"],"is_preprint":false},{"year":2021,"finding":"SCD1-derived PI(18:1/18:1) [1,2-dioleoyl-sn-glycero-3-phospho-(1'-myo-inositol)] is a signaling lipokine that inhibits p38 MAPK activation, counteracts the unfolded protein response (UPR) and ER-associated protein degradation, regulates autophagy, and inhibits apoptosis. SCD1 expression and PI(18:1/18:1) decrease during onset of cell death, repressing PP2A and enhancing stress signaling.","method":"Lipidomics, SCD1 inhibition/deficiency (Scd1-defective mice), exogenous PI(18:1/18:1) supplementation, p38 MAPK assays, UPR markers, PP2A activity assays, multiple cell lines and mouse tissues","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — identification of specific lipid product as signaling molecule, validated across multiple cell lines and mouse tissues with orthogonal biochemical assays","pmids":["35624087"],"is_preprint":false},{"year":2021,"finding":"In X-linked adrenoleukodystrophy (ALD), SCD1 upregulation via chloroquine or LXR agonists shifts saturated very long-chain fatty acids (VLCFAs) toward monounsaturated VLCFAs, reducing ER stress and normalizing phospholipid profiles. Pharmacological SCD1 inhibition increases saturated VLCFAs, and CRISPR knockout of scd1 in zebrafish mimics the ALD motor phenotype.","method":"Drug screen in zebrafish ALD model, SCD1 pharmacological inhibition, CRISPR scd1 knockout in zebrafish, LXR agonist treatment in Abcd1-/y mice, ALD fibroblast ER stress assays, lipidomic analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic and pharmacological models across species with mechanistic readouts linking SCD1 activity to VLCFA saturation and ER stress","pmids":["33690217"],"is_preprint":false},{"year":2021,"finding":"Loss of mitochondrial aconitase (ACO2) increases citrate flux toward fatty acid synthesis and upregulates SCD1, enhancing lipid desaturation to favor colorectal cancer growth. Pharmacological SCD inhibition selectively reduces tumor formation in ACO2-deficient CRC cells.","method":"ACO2 knockdown/overexpression, metabolomics, stable isotope tracing, SCD pharmacological inhibition, tumor formation assays","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — metabolic flux analysis combined with genetic and pharmacological perturbation in single lab","pmids":["33676027"],"is_preprint":false},{"year":2021,"finding":"SCD1 deficiency in SCD1-null mice results in NF-κB pathway activation, increased phosphorylated NF-κB p65 nuclear translocation, upregulation of serine palmitoyltransferase 1 (SPT1), and elevated dihydroceramide synthesis in colorectal cancer cells. Supplemental oleate counteracts SCD1-inhibition-induced NF-κB activation, confirming that reduced MUFA levels are the key mediator.","method":"SCD1 inhibitor treatment, RNA-seq, NF-κB pathway analysis, ceramide measurement, oleate supplementation rescue experiments","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq combined with biochemical rescue assays in single lab establishing SCD1→MUFA→NF-κB→ceramide axis","pmids":["33612070"],"is_preprint":false},{"year":2022,"finding":"SCD1 is a mechanoresponsive enzyme in hepatocellular carcinoma (HCC): high matrix stiffness increases SCD1 expression, which reprograms cellular lipid composition to enhance plasma membrane fluidity and promote HCC invasion and metastasis. Exogenous oleic acid (SCD1 product) mimics the effects of high matrix stiffness, rescuing invasive migration in cells cultured on soft substrates.","method":"Polyacrylamide gel mechanotune culture system, lipidomic analysis, SCD1 genetic knockdown/overexpression, oleic acid supplementation, plasma membrane fluidity assay, in vivo metastasis models","journal":"Molecular therapy","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanically tunable substrate culture, multiple orthogonal methods (lipidomics, genetic, pharmacological, oleic acid rescue) with in vivo validation","pmids":["35358687"],"is_preprint":false},{"year":2022,"finding":"SCD1 inhibition in cancer cells reduces Wnt/β-catenin signaling, enhancing CCL4 production and promoting dendritic cell recruitment into tumors, which increases antitumor CD8+ T cell responses. In CD8+ T cells, SCD1 inhibition reduces ER stress, also enhancing CCL4 production. This dual effect synergizes with anti-PD-1 antibody therapy in mouse tumor models.","method":"SCD1 chemical inhibitor, SCD1 genetic knockout in mice, tumor models, CCL4 ELISA, DC and T cell functional assays, Wnt/β-catenin reporter assays","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological loss-of-function in multiple mouse tumor models, mechanistic dissection of two cell-type-specific pathways, single lab","pmids":["35793868"],"is_preprint":false},{"year":2022,"finding":"SCD1 inhibition in CD8+ T cells reduces oleic acid and esterified cholesterol (generated by ACAT1) levels, directly enhancing IFN-γ production and cytotoxic activity. Addition of oleic acid or cholesteryl oleate reverses the enhanced T cell functions, establishing SCD1→oleic acid→ACAT1→esterified cholesterol as the mechanistic axis suppressing T cell effector function.","method":"SCD1 inhibitor treatment of CD8+ T cells in vitro, oleic acid/cholesteryl oleate supplementation rescue, tumor-infiltrating T cell lipid analysis in vivo, ACAT1 inhibitor experiments","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical rescue experiments establishing lipid intermediate pathway, in vitro and in vivo validation, single lab","pmids":["37879607"],"is_preprint":false},{"year":2022,"finding":"HBXIP transcriptionally induces SCD expression by coactivating the transcription factor ZNF263, resulting in accumulation of free fatty acids that suppress ferroptosis in HCC cells and reduce sensitivity to sorafenib.","method":"HBXIP overexpression/knockdown, ZNF263 coactivation assay, SCD expression analysis, MDA and GSH measurement, ferroptosis assays in vitro and in vivo","journal":"Acta pharmacologica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptional coactivation mechanism identified with functional ferroptosis readout, in vitro and in vivo validation, single lab","pmids":["36109580"],"is_preprint":false},{"year":2022,"finding":"Acidic tumor microenvironment activates the PI3K/AKT signaling pathway to increase SCD1 expression in liver cancer cells. Acidification also promotes direct binding between SCD1 and PPARα, an interaction that dissipates upon pH normalization, suggesting pH-dependent modulation of SCD1-PPARα interaction controls lipid accumulation.","method":"Acidic culture conditions, proteomic analysis, PI3K/AKT pathway inhibitors, SCD1-PPARα co-immunoprecipitation under different pH conditions","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP demonstrating SCD1-PPARα binding under acidic conditions, supported by pathway inhibitor experiments, single lab","pmids":["35046108"],"is_preprint":false},{"year":2022,"finding":"SCD1 is an endoplasmic reticulum-membrane resident enzyme that is enriched in the distal small intestine and colon, and its intestinal-specific deletion (iKO mice) reduces not only intestinal lipids but also plasma triacylglycerols, diacylglycerols, cholesterol esters, and hepatic diacylglycerols. Intestinal SCD1 modulates hepatic de novo lipogenic gene expression via gut-liver crosstalk, potentially through production of the MUFA myristoleic acid.","method":"Intestine-specific SCD1 knockout (iKO) mice, comprehensive targeted lipidomics in intestine/liver/plasma, gene expression analysis of lipogenic genes","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific knockout with comprehensive lipidomic and gene expression profiling establishing gut-liver crosstalk","pmids":["35718096"],"is_preprint":false},{"year":2022,"finding":"Cardiac-specific SCD overexpression (4.9-fold) in transgenic mice causes cardiac hypertrophy and heart failure with reduced ejection fraction (25.7% vs. 54.3% controls). Tg-SCD hearts show increased cardiotoxic saturated lipids (palmitate, stearate), elevated p53, and upregulation of the angiotensin II AT1 receptor. In transfected HEK cells, SCD expression increases the number of cell-surface AT1 receptor binding sites.","method":"Cardiac-specific SCD transgenic mice, echocardiography, whole-genome gene expression profiling, lipid analysis, autoradiography, fluorescence spectroscopy of fluorescent protein-labeled AT1 receptor","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic model with multiple orthogonal readouts (echocardiography, lipidomics, transcriptomics, receptor binding), functional cardiac phenotype","pmids":["34576047"],"is_preprint":false},{"year":2022,"finding":"SCD1 deficiency in keratinocytes impairs integrin α6β4 complex levels and hemidesmosome (HD) assembly, allowing aberrant activation of focal adhesion kinase (FAK) and PI3K, leading to keratinocyte differentiation/proliferation and disruption of the hair follicle bulge niche. PI3K inhibition in Scd1-/- mice normalizes the bulge, hair follicle stem cells, and hair growth. Oleic acid supplementation restores HDs and hair growth.","method":"Scd1 knockout mice (keratinocyte-specific), integrin complex analysis, hemidesmosome imaging, FAK/PI3K activity assays, PI3K inhibitor rescue, oleic acid supplementation rescue","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with dual pharmacological and lipid supplementation rescue, direct mechanistic link between SCD1 product (oleic acid), integrin complex, and hemidesmosome assembly","pmids":["36507562"],"is_preprint":false},{"year":2023,"finding":"ADAR1-mediated A-to-I RNA editing on the 3'UTR of SCD1 mRNA increases binding of the RNA-binding protein KHDRBS1, thereby augmenting SCD1 mRNA stability. Increased SCD1 facilitates lipid droplet formation, alleviates chemotherapy-induced ER stress, and enhances cancer cell self-renewal through increased β-catenin expression.","method":"Patient-derived organoid chemoresistant lines, WES + RNA-seq, A-to-I editing analysis, KHDRBS1 RIP assay, SCD1 mRNA stability assay, SCD1 pharmacological inhibition","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway from RNA editing to mRNA stability validated by RIP assay and multiple functional experiments in physiologically relevant patient-derived organoids","pmids":["37208334"],"is_preprint":false},{"year":2023,"finding":"AKAP8L interacts with SCD1 mRNA and IGF2BP1 protein, regulating SCD1 mRNA stability in an IGF2BP1-dependent manner, thereby promoting gastric cancer cell stemness and chemoresistance to oxaliplatin.","method":"Mass spectrometry protein identification, co-immunoprecipitation of AKAP8L with IGF2BP1, RIP assay for AKAP8L-SCD1 mRNA interaction, AKAP8L overexpression/knockdown with SCD1 rescue","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP and co-IP demonstrating protein-mRNA and protein-protein interactions, functional rescue experiments, single lab","pmids":["36522343"],"is_preprint":false},{"year":2023,"finding":"SCD1 positively regulates squalene epoxidase (SQLE) transcription by eliminating transcriptional inhibition by P53, thereby increasing cholesterol content. Elevated cholesterol regulated by SCD1 inhibits ferroptosis via the mTOR signaling pathway, promoting gastric cancer stem cell (GCSC) stemness.","method":"SCD1 knockdown, SQLE expression and promoter analysis, P53 binding assays, cholesterol measurement, mTOR pathway analysis, in vivo tumor stemness assays","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown with mechanistic promoter and pathway analysis, single lab","pmids":["38972654"],"is_preprint":false},{"year":2023,"finding":"METTL14-mediated m6A modification of SCD1 mRNA increases its recognition by the m6A reader YTHDF2, which destabilizes SCD1 mRNA and diminishes SCD1 expression, thereby suppressing Wnt/β-catenin signaling and colon cancer stemness and metastasis.","method":"METTL14 overexpression/knockdown, m6A methylation analysis of SCD1 mRNA, YTHDF2 RIP assay, mRNA stability assay, Wnt/β-catenin reporter assay","journal":"Molecular biotechnology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — m6A modification and YTHDF2-SCD1 mRNA interaction established by RIP, functional rescue assays, single lab","pmids":["37592151"],"is_preprint":false},{"year":2021,"finding":"HNF4A directly binds to key regulatory regions in the SCD1 locus. Knockdown of HNF4A significantly downregulates SCD1 expression. Two SNPs (rs55710213 and rs56334587) in intron 5 of SCD1 reside in a canonical HNF4A binding site; the GG haplotype disrupts HNF4A binding, reducing enhancer activity and SCD1 expression.","method":"HNF4A ChIP, HNF4A knockdown, luciferase reporter assay with SCD1 regulatory regions, allele-specific HNF4A binding analysis","journal":"Biochimica et biophysica acta. Gene regulatory mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for direct binding combined with reporter assays and knockdown, single lab","pmids":["34171462"],"is_preprint":false},{"year":2021,"finding":"High-fructose diet increases ChREBP binding to the Scd1 gene promoter and enhances histone H3 and H4 acetylation at this promoter, upregulating Scd1 expression in rat liver.","method":"Chromatin immunoprecipitation (ChIP) for ChREBP and histone acetylation at the Scd1 promoter, high-fructose diet rat model, gene expression and triglyceride measurement","journal":"Biomedical research (Tokyo, Japan)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct chromatin-level regulation of Scd1 promoter, single lab","pmids":["33840688"],"is_preprint":false},{"year":2013,"finding":"Genetic ablation of SCD1 alone does not inhibit AKT-driven hepatic steatosis or AKT/Ras-induced hepatocarcinogenesis in mice. SCD2 is strongly upregulated to compensate in SCD1-null liver tumors. Simultaneous silencing of both SCD1 and SCD2 is required to inhibit growth of AKT/Ras cells in vitro.","method":"SCD1 knockout mice, hydrodynamic injection of AKT/Ras oncogenes, liver tumor analysis, SCD2 expression analysis, siRNA co-silencing of SCD1 and SCD2","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic in vivo model with clear negative result (SCD1 dispensable) and mechanistic explanation (SCD2 compensation), key finding for understanding SCD paralogs","pmids":["24069385"],"is_preprint":false},{"year":2024,"finding":"Exercise increases endothelial SCD1 expression, which catalyzes production of oleic acid (OA) and palmitoleic acid (PA), mitigating NF-κB-mediated inflammatory responses. Endothelial-specific Scd1 deletion (Ldlr-/- Scd1EC-/- mice) on high-fat diet results in persistent VCAM1-positive endothelium; SCD1 overexpression via adenovirus mitigates ER stress and inflammatory biomarkers.","method":"Voluntary wheel running exercise, untargeted metabolomics, endothelial-specific Scd1 deletion in mice, adenoviral SCD1 overexpression, single-cell transcriptomics of aorta, inflammatory marker assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific genetic model combined with adenoviral rescue, metabolomics, and single-cell transcriptomics in vivo","pmids":["38354249"],"is_preprint":false},{"year":2024,"finding":"SCD1 inhibition downregulates SLC7A11 expression via the AKT-GSK3β-NRF2 signaling axis, promoting ferroptosis and altering fatty acid metabolism. This mechanism was validated by transcriptomics, lipidomics, and kinase array analysis in preclinical KRASmut LUAD models.","method":"SCD1 inhibition, transcriptomics, lipidomics, kinase array, AKT-GSK3β-NRF2 pathway analysis, xenograft tumor models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-omic approach with pathway validation in preclinical models, single lab","pmids":["40198901"],"is_preprint":false},{"year":2024,"finding":"SCD1 knockdown in cardiac fibroblasts activates PGC1α and PPARβ signaling, enhancing fatty acid oxidation (FAO)-related gene expression and mitochondrial biogenesis, thereby improving cardiac reprogramming efficiency (conversion of fibroblasts to induced cardiomyocytes).","method":"Scd1 knockdown, single-cell metabolic flux estimation, flux balance analysis, PGC1α/PPARβ pathway analysis, pharmacological SCD1 inhibition, mitochondrial biogenesis assays","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological manipulation with pathway analysis and metabolic modeling, single lab","pmids":["40007118"],"is_preprint":false},{"year":2024,"finding":"METTL16-mediated m6A modification of SCD1 mRNA increases its degradation via the m6A reader YTHDC2. METTL16 downregulation (due to DNMT1-mediated promoter hypermethylation) reduces m6A on SCD1 mRNA, increasing SCD1 expression and lipid metabolism, promoting papillary thyroid cancer progression.","method":"METTL16 gain/loss-of-function, m6A abundance measurement on SCD1 mRNA, YTHDC2 reader assay, RNA decay assay, SCD1 inhibitor A939572","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — m6A modification and YTHDC2 reader-dependent RNA decay established, functional consequences validated, single lab","pmids":["38334797"],"is_preprint":false},{"year":2024,"finding":"IGF2BP3 regulates SCD mRNA m6A modifications via an IGF2BP3-METTL14 complex, enhancing SCD mRNA stability and thereby promoting lipid metabolism, proliferation, and metastasis in cervical cancer. RIP assay confirmed IGF2BP3 binding to SCD mRNA.","method":"RNA-seq target identification, RIP assay for IGF2BP3-SCD mRNA binding, methylated RNA immunoprecipitation (MeRIP), IGF2BP3 knockdown with SCD overexpression rescue, in vivo tumor model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP and MeRIP establish binding and m6A regulation of SCD, rescue experiments confirm functional axis, single lab","pmids":["38355626"],"is_preprint":false},{"year":2024,"finding":"LDHA-mediated histone H3K18 lactylation is enriched on the METTL3 promoter, upregulating METTL3 expression. METTL3 increases m6A modification of SCD1 mRNA, recognized by YTHDF1 which stabilizes SCD1 mRNA, promoting lipid accumulation and NAFLD progression.","method":"IP and dual-luciferase reporter for H3K18lac on METTL3 promoter, METTL3/LDHA knockdown, m6A measurement of SCD1 mRNA, YTHDF1 RIP, RNA decay assay","journal":"Physiological research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chromatin modification, m6A, and RBP-mRNA interaction chain experimentally established, single lab","pmids":["39903889"],"is_preprint":false},{"year":2022,"finding":"SCD1 inhibition in colorectal cancer cells decreases MUFA levels, activates NF-κB pathway and de novo ceramide synthesis. A separate study (Liu et al.) shows TIGAR inhibition represses SCD1 expression in a ROS/AMPK-dependent manner, rendering colorectal cancer cells more sensitive to ferroptosis.","method":"SCD1 inhibitor, TIGAR knockdown, AMPK activation assay, ROS measurement, ferroptosis markers (MDA, GSH/GSSG, lipid peroxidation)","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological manipulation establishing TIGAR→ROS/AMPK→SCD1 axis, single lab","pmids":["35271998"],"is_preprint":false},{"year":2023,"finding":"Nodal overexpression transcriptionally upregulates SCD1 via Smad2/3 pathway activation, inducing monounsaturated fatty acid synthesis and protecting colorectal cancer cells from ferroptosis. SCD1 inhibition at least partially abolishes the resistance of Nodal-overexpressing cells to RSL3-induced ferroptosis.","method":"Nodal overexpression/knockdown, Smad2/3 pathway analysis, SCD1 luciferase reporter, lipid peroxidation assays, ferroptosis induction, in vivo tumor models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptional mechanism via Smad2/3 to SCD1 promoter validated, functional ferroptosis rescue, single lab","pmids":["37002201"],"is_preprint":false},{"year":2024,"finding":"SCD1 inhibition (via the RIFSP-2 peptide) limits MUFA biogenesis and decreases radiation-induced STING-mediated inflammation and pyroptosis. RIFSP-2 was identified as a direct binding target of SCD1 via a streptavidin-biotin pull-down system; lipidomic analysis confirmed that RIFSP-2 treatment restrains MUFA biogenesis.","method":"Streptavidin-biotin pull-down to identify SCD1 as RIFSP-2 target, lipidomics, STING pathway analysis, in vivo irradiation model","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding identification via pull-down, lipidomic functional validation, single lab","pmids":["38582510"],"is_preprint":false},{"year":2024,"finding":"SULT2B1 directly interacts with SCD1 to facilitate lipid metabolism and promote colon cancer metastasis. Combined application of SCD1 inhibitor and SULT2B1 knockout showed a more robust inhibitory effect on lipid metabolism and metastasis than SULT2B1 knockout alone.","method":"Co-immunoprecipitation of SULT2B1 with SCD1, SULT2B1 knockout, SCD1 inhibitor CAY, lipid metabolism assays, orthotopic tumor model","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP demonstrating direct protein interaction, synergistic pharmacological/genetic evidence, single lab","pmids":["38372484"],"is_preprint":false},{"year":2024,"finding":"Specific SCD1 inhibition in primary proximal tubular epithelial cells activates cGAS/STING signaling, and HDD treatment of renal fibrosis restores SCD1 expression while suppressing this pathway. This places SCD1 upstream of cGAS/STING signaling in renal tubular cells.","method":"SCD1 inhibitor A939572 in primary PTECs, cGAS/STING signaling markers, renal fibrosis mouse model, lipidomics","journal":"Journal of ethnopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological SCD1 inhibition directly activating cGAS/STING validated in primary cells and in vivo, single lab","pmids":["39832629"],"is_preprint":false},{"year":2024,"finding":"Scd1 deficiency in adipocytes impairs autophagosome-lysosome fusion and lysosomal/autolysosomal acidification, leading to vacuole accumulation and cell death. Supplementation with monounsaturated fatty acids restores viability of Scd1-deficient adipocytes. In vivo, Scd1 deletion leads to loss of bone marrow adipocytes through autophagy-dependent cell death.","method":"Scd1 knockout adipocytes and mouse models, pharmacological SCD1 inhibition, autophagy flux assays, MUFA supplementation rescue, autophagosome formation inhibitor","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout in vitro and in vivo with pharmacological inhibition and MUFA rescue, directly establishing SCD1→MUFA→autophagosome-lysosome fusion","pmids":["38492843"],"is_preprint":false},{"year":2023,"finding":"SCD1 in sebocytes catalyzes the Δ9 desaturation of palmitate (C16:0) to palmitoleate (C16:1n-7), while FADS2 catalyzes Δ6 desaturation to sapienate (C16:1n-10). Specific inhibition of SCD1 in SZ95 sebocytes enhances lipoinflammation induced by saturated fatty acids, indicating that SCD1-mediated desaturation normally limits inflammatory responses in sebaceous cells.","method":"Specific SCD1 and FADS2 inhibitors in SZ95 sebocytes, fatty acid profiling, IL-6/IL-8 cytokine measurement, lipid quantification","journal":"Experimental dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of SCD1 vs FADS2 desaturation pathways with functional inflammatory readout, single lab","pmids":["36843338"],"is_preprint":false}],"current_model":"SCD1 (stearoyl-CoA desaturase 1) is an endoplasmic reticulum-resident enzyme that catalyzes the rate-limiting Δ9-desaturation of saturated fatty acids (principally palmitoyl- and stearoyl-CoA) to generate monounsaturated fatty acids (MUFAs), primarily palmitoleate and oleate; these MUFAs in turn serve as structural components of membrane phospholipids, substrates for triglyceride synthesis, and signaling lipids (e.g., PI(18:1/18:1)) that suppress p38/UPR/apoptosis stress pathways, modulate AMPK/SIRT1 activity and histone acetylation through effects on AMP/ATP ratios, activate SREBP-1 nuclear accumulation to sustain lipogenesis, maintain hemidesmosome integrity via integrin α6β4, regulate plasma membrane fluidity to control cell invasion, and protect against ferroptosis by limiting polyunsaturated fatty acid availability for lipid peroxidation; its transcriptional regulation involves MITF, HNF4A, ChREBP (via histone acetylation), HBXIP-ZNF263, and Smad2/3, while its mRNA stability is controlled post-transcriptionally by ADAR1-mediated RNA editing recruiting KHDRBS1 and by multiple m6A writer-reader systems (METTL3-YTHDF1, METTL14-YTHDF2, METTL16-YTHDC2)."},"narrative":{"mechanistic_narrative":"SCD (stearoyl-CoA desaturase 1) is an endoplasmic reticulum-resident enzyme that catalyzes the rate-limiting Δ9-desaturation of saturated fatty acids into monounsaturated fatty acids (MUFAs), a reaction central to de novo lipogenesis and fat cell metabolism [PMID:7480063, PMID:35718096]. Its principal products—oleate and palmitoleate—act not only as building blocks for membrane and storage lipids but as signaling intermediates: oleate drives SREBP-1 nuclear accumulation to sustain lipogenesis [PMID:28851735], modulates the AMP/ATP ratio to control AMPK→SIRT1→histone acetylation [PMID:31241768], and the specific phospholipid PI(18:1/18:1) suppresses p38 MAPK, the unfolded protein response, and apoptosis while regulating autophagy [PMID:35624087]. By converting saturated very-long-chain and palmitoyl/stearoyl species to MUFAs, SCD limits ER stress, NF-κB-driven inflammation, and ceramide accumulation across endothelium, sebocytes, intestine, and disease models [PMID:33690217, PMID:33612070, PMID:38354249, PMID:36843338], and supports autophagosome–lysosome fusion required for adipocyte viability [PMID:38492843]. A recurrent theme is SCD's protection against ferroptosis: by enriching cells in anti-peroxidative MUFAs and influencing cholesterol and SLC7A11 metabolism, it confers resistance to ferroptosis inducers and chemotherapy in multiple cancers [PMID:33296645, PMID:36109580, PMID:38972654, PMID:40198901, PMID:37002201]. SCD is heavily controlled at multiple regulatory layers—transcriptionally by MITF, HNF4A, ChREBP, HBXIP-ZNF263, and Nodal/Smad2/3 [PMID:31733993, PMID:34171462, PMID:33840688, PMID:36109580, PMID:37002201], and post-transcriptionally through ADAR1-KHDRBS1 RNA editing and several m6A writer–reader systems (METTL14-YTHDF2, METTL16-YTHDC2, METTL3-YTHDF1) that tune SCD mRNA stability [PMID:37208334, PMID:37592151, PMID:38334797, PMID:39903889]. In cancer SCD frequently promotes invasion, stemness, and immune evasion—membrane-fluidity-dependent invasion under matrix stiffness [PMID:35358687], suppression of CD8+ T cell effector function via oleate/ACAT1 [PMID:37879607], and stem-cell self-renewal [PMID:37208334]—though its dispensability can be masked by paralog SCD2 compensation [PMID:24069385]. Pharmacological SCD1 inhibition is contextually linked to motor phenotypes in adrenoleukodystrophy and cardiac, renal, and inflammatory disease models [PMID:33690217, PMID:34576047, PMID:39832629].","teleology":[{"year":1995,"claim":"Established SCD1 as the rate-limiting desaturase converting saturated fatty acids to MUFAs, defining its core enzymatic role in lipogenesis and fat metabolism.","evidence":"Review synthesizing biochemical and molecular studies of the SCD gene family","pmids":["7480063"],"confidence":"High","gaps":["Does not resolve isoform/paralog-specific substrate preferences in vivo","No structural mechanism of catalysis provided"]},{"year":2013,"claim":"Showed SCD1 is genetically dispensable for AKT/Ras-driven hepatocarcinogenesis because paralog SCD2 compensates, defining when targeting SCD1 alone fails.","evidence":"SCD1 knockout mice with AKT/Ras hydrodynamic injection plus siRNA co-silencing of SCD1/SCD2","pmids":["24069385"],"confidence":"High","gaps":["Tissue/tumor contexts where SCD2 compensation does not occur not delineated","No combined pharmacological dual-inhibitor validation in vivo"]},{"year":2017,"claim":"Identified the SCD1 product oleate as the signal that restores SREBP-1 nuclear accumulation and lipogenesis, linking enzyme output to a transcriptional feed-forward loop.","evidence":"Scd1-deficient and liver-specific oleate/palmitoleate transgenic mice with hepatocyte SREBP-1 assays","pmids":["28851735"],"confidence":"High","gaps":["Molecular mechanism by which oleate promotes SREBP-1 processing unresolved","Relative contribution of oleate vs palmitoleate not separated"]},{"year":2019,"claim":"Connected SCD1 activity to cellular energy state, showing it controls AMP/ATP ratio, AMPK, NAD+/SIRT1, and histone acetylation in muscle.","evidence":"SCD1 knockout and muscle-specific overexpression mice with metabolic and epigenetic readouts","pmids":["31241768"],"confidence":"High","gaps":["Direct biochemical link between MUFA levels and AMP generation not defined","Generality beyond skeletal muscle unclear"]},{"year":2019,"claim":"Defined a lineage-restricted MITF-SCD transcriptional axis required for MITFHigh melanoma proliferation, establishing context-dependent SCD dependency.","evidence":"Genetic/pharmacological SCD perturbation with MITF modulation, proliferation/invasion and in vivo metastasis assays","pmids":["31733993"],"confidence":"High","gaps":["Direct MITF binding to SCD promoter not detailed","Mechanism of MITFLow insensitivity unresolved"]},{"year":2021,"claim":"Identified the specific SCD1-derived lipokine PI(18:1/18:1) as a suppressor of p38/UPR/apoptosis and regulator of autophagy and PP2A, elevating SCD1 from metabolic enzyme to signaling hub.","evidence":"Lipidomics, Scd1-defective mice, exogenous PI(18:1/18:1) supplementation, p38/UPR/PP2A assays across cell lines and tissues","pmids":["35624087"],"confidence":"High","gaps":["Direct molecular target/receptor of PI(18:1/18:1) not identified","How PI(18:1/18:1) represses PP2A mechanistically unclear"]},{"year":2021,"claim":"Demonstrated that SCD1-mediated shift from saturated to monounsaturated VLCFAs reduces ER stress, linking SCD1 to adrenoleukodystrophy pathology.","evidence":"Zebrafish ALD drug screen and CRISPR scd1 knockout, LXR agonists in Abcd1-/y mice, ALD fibroblast ER stress and lipidomics","pmids":["33690217"],"confidence":"High","gaps":["Whether SCD1 modulation is therapeutic in human ALD not established","Mechanism of VLCFA recognition by SCD1 not defined"]},{"year":2021,"claim":"Linked SCD1 to multiple upstream metabolic and transcriptional regulators (ACO2 citrate flux, HNF4A binding, ChREBP/histone acetylation), building the input map for SCD1 expression.","evidence":"ACO2 perturbation with isotope tracing; HNF4A ChIP/knockdown/reporter with SNP analysis; ChREBP/histone ChIP in fructose-fed rats","pmids":["33676027","34171462","33840688"],"confidence":"Medium","gaps":["Cross-tissue generality of each regulatory input not tested","Interplay among these regulators on the SCD1 locus unresolved"]},{"year":2020,"claim":"Established SCD1 as a downstream effector protecting cancer cells from ferroptosis via MUFA production, regulated by lactate/MCT1-AMPK-SREBP1 and FBW7-NR4A1 axes.","evidence":"MCT1 and FBW7/NR4A1 perturbation, AMPK/SREBP1 modulation, ferroptosis assays in vitro and in xenografts","pmids":["33296645","33271455"],"confidence":"Medium","gaps":["Direct promoter/binding evidence for FBW7-NR4A1-SCD1 lacking","Quantitative contribution of SCD1 vs other anti-ferroptotic factors unclear"]},{"year":2022,"claim":"Showed SCD1 is mechanoresponsive and promotes invasion by remodeling membrane fluidity, while also reprogramming the antitumor immune microenvironment.","evidence":"Mechanotunable substrate culture, lipidomics, genetic/pharmacological SCD1 manipulation with oleic acid rescue, plus tumor immune models (CCL4, DC/CD8 assays, anti-PD-1)","pmids":["35358687","35793868","37879607"],"confidence":"Medium","gaps":["Mechanism converting membrane fluidity to invasion signaling not defined","Direct sensor coupling matrix stiffness to SCD1 transcription unknown"]},{"year":2022,"claim":"Extended SCD1's protective MUFA function to tissue physiology—hemidesmosome/integrin α6β4 integrity in keratinocytes, cardiac lipotoxicity on overexpression, and gut-liver lipid crosstalk.","evidence":"Keratinocyte-specific Scd1 KO with PI3K-inhibitor and oleate rescue; cardiac-specific SCD transgenic mice; intestine-specific SCD1 KO with lipidomics","pmids":["36507562","34576047","35718096"],"confidence":"High","gaps":["Mechanism linking MUFA supply to integrin complex stability unresolved","AT1 receptor upregulation mechanism in cardiac overexpression not defined"]},{"year":2022,"claim":"Identified protein-level and microenvironmental regulators of SCD1 (HBXIP-ZNF263 transcription, pH-dependent SCD1-PPARα binding), expanding its regulatory inputs.","evidence":"HBXIP/ZNF263 coactivation assays with ferroptosis readouts; proteomics and pH-dependent SCD1-PPARα co-IP with PI3K/AKT inhibitors","pmids":["36109580","35046108"],"confidence":"Medium","gaps":["Functional consequence of SCD1-PPARα interaction not mechanistically resolved","Single co-IP basis for the SCD1-PPARα interaction"]},{"year":2023,"claim":"Defined post-transcriptional control of SCD1 by ADAR1 A-to-I editing recruiting KHDRBS1, and AKAP8L/IGF2BP1, that stabilize SCD1 mRNA to drive cancer stemness and chemoresistance.","evidence":"Patient-derived organoids, RNA editing and RIP assays, mRNA stability assays, co-IP, with SCD1 inhibition","pmids":["37208334","36522343"],"confidence":"Medium","gaps":["Whether editing and m6A pathways converge on the same transcripts unknown","AKAP8L-IGF2BP1-SCD1 axis from single lab without reciprocal validation"]},{"year":2023,"claim":"Established m6A writer-reader control of SCD1 mRNA stability (METTL14-YTHDF2) and SCD1's downstream control of SQLE/cholesterol and Wnt/β-catenin in cancer stemness and ferroptosis.","evidence":"MeRIP/RIP, mRNA decay assays, SQLE promoter and P53 binding analysis, Nodal/Smad2/3 reporter, ferroptosis assays","pmids":["37592151","38972654","37002201"],"confidence":"Medium","gaps":["Cell-type specificity of opposing m6A reader outcomes unresolved","Direct vs indirect SCD1 control of SQLE transcription not fully separated"]},{"year":2024,"claim":"Broadened SCD1's physiological roles—endothelial anti-inflammatory protection during exercise, adipocyte autophagy/lysosomal function, and cardiac reprogramming—through MUFA-dependent mechanisms.","evidence":"Endothelial-specific Scd1 KO with adenoviral rescue and single-cell transcriptomics; Scd1 KO adipocytes with MUFA rescue and autophagy flux; cardiac fibroblast Scd1 knockdown with metabolic flux modeling","pmids":["38354249","38492843","40007118"],"confidence":"High","gaps":["Mechanism by which MUFAs support lysosomal acidification unresolved","Generalizability of endothelial findings beyond Ldlr-/- model untested"]},{"year":2024,"claim":"Connected SCD1 inhibition to innate immune and ferroptotic stress pathways (cGAS/STING, AKT-GSK3β-NRF2-SLC7A11) and identified direct SCD1-binding modulators (RIFSP-2, SULT2B1).","evidence":"SCD1 inhibitors with transcriptomics/lipidomics/kinase arrays, cGAS/STING markers, biotin pull-down and co-IP, in vivo tumor/fibrosis/irradiation models","pmids":["40198901","39832629","38582510","38372484"],"confidence":"Medium","gaps":["Direct molecular events linking MUFA loss to STING activation not defined","SCD1-SULT2B1 interaction from single co-IP without structural detail"]},{"year":2024,"claim":"Resolved additional m6A regulatory systems controlling SCD1 mRNA (METTL16-YTHDC2, METTL3-YTHDF1, IGF2BP3-METTL14), showing layered and tissue-specific tuning of SCD1 in cancer and NAFLD.","evidence":"Gain/loss-of-function of m6A enzymes, m6A abundance and reader RIP assays, RNA decay assays, H3K18lac/promoter analysis, in vivo models","pmids":["38334797","39903889","38355626"],"confidence":"Medium","gaps":["Hierarchy and competition among the multiple m6A reader systems on SCD1 unknown","Each axis established in a single tumor context"]},{"year":null,"claim":"How the diverse upstream regulators and the distinct MUFA-derived signals (PI(18:1/18:1), oleate, palmitoleate) are integrated to produce context-specific outcomes—ferroptosis resistance, invasion, immune suppression, or tissue protection—remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model coupling specific lipid products to specific downstream effectors","Structural basis of SCD1 desaturation and substrate selectivity not addressed in corpus","Predictors of SCD1 dependency vs SCD2 compensation across tissues undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,37]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,37]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,15]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,6,32,36]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[18,21,28,30]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,17]}],"complexes":[],"partners":["PPARA","SULT2B1","KHDRBS1","IGF2BP1","AKAP8L"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O00767","full_name":"Stearoyl-CoA desaturase","aliases":["Acyl-CoA desaturase","Delta(9)-desaturase","Delta-9 desaturase","Fatty acid desaturase"],"length_aa":359,"mass_kda":41.5,"function":"Stearoyl-CoA desaturase that utilizes O(2) and electrons from reduced cytochrome b5 to introduce the first double bond into saturated fatty acyl-CoA substrates (PubMed:15907797, PubMed:18765284). Catalyzes the insertion of a cis double bond at the delta-9 position into fatty acyl-CoA substrates including palmitoyl-CoA and stearoyl-CoA (PubMed:15907797, PubMed:18765284). Gives rise to a mixture of 16:1 and 18:1 unsaturated fatty acids (PubMed:15610069). Plays an important role in lipid biosynthesis. Plays an important role in regulating the expression of genes that are involved in lipogenesis and in regulating mitochondrial fatty acid oxidation (By similarity). Plays an important role in body energy homeostasis (By similarity). Contributes to the biosynthesis of membrane phospholipids, cholesterol esters and triglycerides (By similarity)","subcellular_location":"Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/O00767/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/SCD","classification":"Common Essential","n_dependent_lines":852,"n_total_lines":1208,"dependency_fraction":0.7052980132450332},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000099194","cell_line_id":"CID000321","localizations":[{"compartment":"vesicles","grade":3},{"compartment":"er","grade":2}],"interactors":[{"gene":"ARHGAP15","stoichiometry":0.2},{"gene":"BCAP31","stoichiometry":0.2},{"gene":"DDOST","stoichiometry":0.2},{"gene":"ESYT1","stoichiometry":0.2},{"gene":"OST4","stoichiometry":0.2},{"gene":"PGRMC1","stoichiometry":0.2},{"gene":"RPN1","stoichiometry":0.2},{"gene":"RPN2","stoichiometry":0.2},{"gene":"RTN4","stoichiometry":0.2},{"gene":"TTC27","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000321","total_profiled":1310},"omim":[{"mim_id":"619815","title":"ATPase, PHOSPHOLIPID-TRANSPORTING, 10D; ATP10D","url":"https://www.omim.org/entry/619815"},{"mim_id":"616312","title":"LEM DOMAIN-CONTAINING PROTEIN 2; LEMD2","url":"https://www.omim.org/entry/616312"},{"mim_id":"616240","title":"OLIGODENDROCYTE MATURATION-ASSOCIATED LONG INTERGENIC NONCODING RNA; OLMALINC","url":"https://www.omim.org/entry/616240"},{"mim_id":"613101","title":"HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 5, WITH OR WITHOUT MICROVILLUS INCLUSION DISEASE; FHL5","url":"https://www.omim.org/entry/613101"},{"mim_id":"612350","title":"EHLERS-DANLOS SYNDROME, SPONDYLODYSPLASTIC TYPE, 3; EDSSPD3","url":"https://www.omim.org/entry/612350"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Endoplasmic reticulum","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adipose tissue","ntpm":1158.4},{"tissue":"brain","ntpm":979.4},{"tissue":"liver","ntpm":546.1}],"url":"https://www.proteinatlas.org/search/SCD"},"hgnc":{"alias_symbol":["FADS5","SCD1"],"prev_symbol":["SCDOS"]},"alphafold":{"accession":"O00767","domains":[{"cath_id":"-","chopping":"74-272","consensus_level":"high","plddt":98.1699,"start":74,"end":272}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00767","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00767-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00767-F1-predicted_aligned_error_v6.png","plddt_mean":89.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SCD","jax_strain_url":"https://www.jax.org/strain/search?query=SCD"},"sequence":{"accession":"O00767","fasta_url":"https://rest.uniprot.org/uniprotkb/O00767.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00767/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00767"}},"corpus_meta":[{"pmid":"33296645","id":"PMC_33296645","title":"HCAR1/MCT1 Regulates Tumor Ferroptosis through the Lactate-Mediated AMPK-SCD1 Activity and Its Therapeutic Implications.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33296645","citation_count":352,"is_preprint":false},{"pmid":"7480063","id":"PMC_7480063","title":"The regulation of stearoyl-CoA desaturase (SCD).","date":"1995","source":"Progress in lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/7480063","citation_count":285,"is_preprint":false},{"pmid":"34030117","id":"PMC_34030117","title":"Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence.","date":"2021","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/34030117","citation_count":231,"is_preprint":false},{"pmid":"31226399","id":"PMC_31226399","title":"Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.","date":"2019","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31226399","citation_count":220,"is_preprint":false},{"pmid":"33271455","id":"PMC_33271455","title":"FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells.","date":"2020","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/33271455","citation_count":218,"is_preprint":false},{"pmid":"33264619","id":"PMC_33264619","title":"Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33264619","citation_count":200,"is_preprint":false},{"pmid":"34429143","id":"PMC_34429143","title":"SCD1, autophagy and cancer: implications for therapy.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/34429143","citation_count":121,"is_preprint":false},{"pmid":"31733993","id":"PMC_31733993","title":"Lineage-Restricted Regulation of SCD and Fatty Acid Saturation by MITF Controls Melanoma Phenotypic Plasticity.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/31733993","citation_count":106,"is_preprint":false},{"pmid":"29101357","id":"PMC_29101357","title":"MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29101357","citation_count":99,"is_preprint":false},{"pmid":"35271998","id":"PMC_35271998","title":"TIGAR drives colorectal cancer ferroptosis resistance through ROS/AMPK/SCD1 pathway.","date":"2022","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35271998","citation_count":93,"is_preprint":false},{"pmid":"37208334","id":"PMC_37208334","title":"ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37208334","citation_count":89,"is_preprint":false},{"pmid":"38042113","id":"PMC_38042113","title":"SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/38042113","citation_count":89,"is_preprint":false},{"pmid":"35485210","id":"PMC_35485210","title":"Long noncoding RNA LINC01606 protects colon cancer cells from ferroptotic cell death and promotes stemness by SCD1-Wnt/β-catenin-TFE3 feedback loop signalling.","date":"2022","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35485210","citation_count":89,"is_preprint":false},{"pmid":"35358687","id":"PMC_35358687","title":"An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming.","date":"2022","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35358687","citation_count":84,"is_preprint":false},{"pmid":"35793868","id":"PMC_35793868","title":"Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35793868","citation_count":83,"is_preprint":false},{"pmid":"36109580","id":"PMC_36109580","title":"Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma.","date":"2022","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/36109580","citation_count":73,"is_preprint":false},{"pmid":"35526323","id":"PMC_35526323","title":"Agrimonolide inhibits cancer progression and induces ferroptosis and apoptosis by targeting SCD1 in ovarian cancer cells.","date":"2022","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35526323","citation_count":63,"is_preprint":false},{"pmid":"39353532","id":"PMC_39353532","title":"Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/39353532","citation_count":60,"is_preprint":false},{"pmid":"28970336","id":"PMC_28970336","title":"SCD1 and SCD2 Form a Complex That Functions with the Exocyst and RabE1 in Exocytosis and Cytokinesis.","date":"2017","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/28970336","citation_count":58,"is_preprint":false},{"pmid":"28851735","id":"PMC_28851735","title":"Oleate activates SREBP-1 signaling activity in SCD1-deficient hepatocytes.","date":"2017","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28851735","citation_count":56,"is_preprint":false},{"pmid":"35624087","id":"PMC_35624087","title":"PI(18:1/18:1) is a SCD1-derived lipokine that limits stress signaling.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35624087","citation_count":48,"is_preprint":false},{"pmid":"31241768","id":"PMC_31241768","title":"SCD1 regulates the AMPK/SIRT1 pathway and histone acetylation through changes in adenine nucleotide metabolism in skeletal muscle.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31241768","citation_count":45,"is_preprint":false},{"pmid":"33676027","id":"PMC_33676027","title":"Loss of mitochondrial aconitase promotes colorectal cancer progression via SCD1-mediated lipid remodeling.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33676027","citation_count":44,"is_preprint":false},{"pmid":"32873775","id":"PMC_32873775","title":"Sulforaphene inhibits esophageal cancer progression via suppressing SCD and CDH3 expression, and activating the GADD45B-MAP2K3-p38-p53 feedback loop.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32873775","citation_count":39,"is_preprint":false},{"pmid":"33072956","id":"PMC_33072956","title":"Newborn Screening for SCD in the USA and Canada.","date":"2018","source":"International journal of neonatal screening","url":"https://pubmed.ncbi.nlm.nih.gov/33072956","citation_count":38,"is_preprint":false},{"pmid":"32035613","id":"PMC_32035613","title":"MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32035613","citation_count":38,"is_preprint":false},{"pmid":"30791926","id":"PMC_30791926","title":"Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30791926","citation_count":37,"is_preprint":false},{"pmid":"8251957","id":"PMC_8251957","title":"Psychosocial aspects of sickle cell disease (SCD) in childhood and adolescence: a review.","date":"1993","source":"The British journal of clinical psychology","url":"https://pubmed.ncbi.nlm.nih.gov/8251957","citation_count":36,"is_preprint":false},{"pmid":"38334797","id":"PMC_38334797","title":"METTL16 inhibits papillary thyroid cancer tumorigenicity through m6A/YTHDC2/SCD1-regulated lipid metabolism.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38334797","citation_count":36,"is_preprint":false},{"pmid":"31118017","id":"PMC_31118017","title":"Sudden Cardiac Death (SCD) - risk stratification and prediction with molecular biomarkers.","date":"2019","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/31118017","citation_count":34,"is_preprint":false},{"pmid":"33690217","id":"PMC_33690217","title":"Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33690217","citation_count":33,"is_preprint":false},{"pmid":"35366607","id":"PMC_35366607","title":"Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model.","date":"2022","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35366607","citation_count":33,"is_preprint":false},{"pmid":"32996649","id":"PMC_32996649","title":"N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPARα and SCD-1.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32996649","citation_count":33,"is_preprint":false},{"pmid":"38355626","id":"PMC_38355626","title":"IGF2BP3 enhances lipid metabolism in cervical cancer by upregulating the expression of SCD.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38355626","citation_count":31,"is_preprint":false},{"pmid":"36868847","id":"PMC_36868847","title":"Predictors of cognitive deterioration in subjective cognitive decline: evidence from longitudinal studies and implications for SCD-plus criteria.","date":"2023","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/36868847","citation_count":31,"is_preprint":false},{"pmid":"36889082","id":"PMC_36889082","title":"Inhibiting SCD expression by IGF1R during lorlatinib therapy sensitizes melanoma to ferroptosis.","date":"2023","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/36889082","citation_count":29,"is_preprint":false},{"pmid":"37879607","id":"PMC_37879607","title":"SCD1 inhibition enhances the effector functions of CD8+ T cells via ACAT1-dependent reduction of esterified cholesterol.","date":"2023","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/37879607","citation_count":29,"is_preprint":false},{"pmid":"37002201","id":"PMC_37002201","title":"Nodal promotes colorectal cancer survival and metastasis through regulating SCD1-mediated ferroptosis resistance.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37002201","citation_count":29,"is_preprint":false},{"pmid":"36672408","id":"PMC_36672408","title":"CircZBTB46 Protects Acute Myeloid Leukemia Cells from Ferroptotic Cell Death by Upregulating SCD.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36672408","citation_count":29,"is_preprint":false},{"pmid":"40198901","id":"PMC_40198901","title":"SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.","date":"2025","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/40198901","citation_count":23,"is_preprint":false},{"pmid":"35718096","id":"PMC_35718096","title":"SCD1 is nutritionally and spatially regulated in the intestine and influences systemic postprandial lipid homeostasis and gut-liver crosstalk.","date":"2022","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/35718096","citation_count":21,"is_preprint":false},{"pmid":"38372484","id":"PMC_38372484","title":"Sulfotransferase SULT2B1 facilitates colon cancer metastasis by promoting SCD1-mediated lipid metabolism.","date":"2024","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38372484","citation_count":21,"is_preprint":false},{"pmid":"24069385","id":"PMC_24069385","title":"SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24069385","citation_count":20,"is_preprint":false},{"pmid":"36897914","id":"PMC_36897914","title":"A high-throughput newborn screening approach for SCID, SMA, and SCD combining multiplex qPCR and tandem mass spectrometry.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36897914","citation_count":20,"is_preprint":false},{"pmid":"33072971","id":"PMC_33072971","title":"The Neonatal Screening Program in Brazil, Focus on Sickle Cell Disease (SCD).","date":"2019","source":"International journal of neonatal screening","url":"https://pubmed.ncbi.nlm.nih.gov/33072971","citation_count":20,"is_preprint":false},{"pmid":"24780075","id":"PMC_24780075","title":"Association of BTG2, CYR61, ZFP36, and SCD gene polymorphisms with Graves' disease and ophthalmopathy.","date":"2014","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/24780075","citation_count":20,"is_preprint":false},{"pmid":"36008942","id":"PMC_36008942","title":"Selenocysteine Machinery Primarily Supports TXNRD1 and GPX4 Functions and Together They Are Functionally Linked with SCD and PRDX6.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36008942","citation_count":20,"is_preprint":false},{"pmid":"36627645","id":"PMC_36627645","title":"TGF-β1 promotes SCD1 expression via the PI3K-Akt-mTOR-SREBP1 signaling pathway in lung fibroblasts.","date":"2023","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/36627645","citation_count":19,"is_preprint":false},{"pmid":"38972654","id":"PMC_38972654","title":"SCD1 promotes the stemness of gastric cancer stem cells by inhibiting ferroptosis through the SQLE/cholesterol/mTOR signalling pathway.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38972654","citation_count":19,"is_preprint":false},{"pmid":"36522343","id":"PMC_36522343","title":"AKAP8L enhances the stemness and chemoresistance of gastric cancer cells by stabilizing SCD1 mRNA.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36522343","citation_count":19,"is_preprint":false},{"pmid":"34487059","id":"PMC_34487059","title":"The Effects of Treatment with Blood Transfusion, Iron Chelation and Hydroxyurea on Puberty, Growth and Spermatogenesis in Sickle Cell Disease (SCD): A short update.","date":"2021","source":"Acta bio-medica : Atenei Parmensis","url":"https://pubmed.ncbi.nlm.nih.gov/34487059","citation_count":19,"is_preprint":false},{"pmid":"32392704","id":"PMC_32392704","title":"Expression of SCD and FADS2 Is Lower in the Necrotic Core and Growing Tumor Area than in the Peritumoral Area of Glioblastoma Multiforme.","date":"2020","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32392704","citation_count":18,"is_preprint":false},{"pmid":"35046108","id":"PMC_35046108","title":"Tumor Microenvironment Acidity Triggers Lipid Accumulation in Liver Cancer via SCD1 Activation.","date":"2022","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/35046108","citation_count":18,"is_preprint":false},{"pmid":"38354249","id":"PMC_38354249","title":"Exercise mitigates flow recirculation and activates metabolic transducer SCD1 to catalyze vascular protective metabolites.","date":"2024","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/38354249","citation_count":16,"is_preprint":false},{"pmid":"38582510","id":"PMC_38582510","title":"A Frog Skin-Derived Peptide Targeting SCD1 Exerts Radioprotective Effects Against Skin Injury by Inhibiting STING-Mediated Inflammation.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38582510","citation_count":16,"is_preprint":false},{"pmid":"39399463","id":"PMC_39399463","title":"Formononetin triggers ferroptosis in triple-negative breast cancer cells by regulating the mTORC1/SREBP1/SCD1 pathway.","date":"2024","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39399463","citation_count":15,"is_preprint":false},{"pmid":"38072968","id":"PMC_38072968","title":"Circular RNA RHBDD1 regulates tumorigenicity and ferroptosis in colorectal cancer by mediating the ELAVL1/SCD mRNA interaction.","date":"2023","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38072968","citation_count":15,"is_preprint":false},{"pmid":"36604142","id":"PMC_36604142","title":"MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors.","date":"2022","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/36604142","citation_count":15,"is_preprint":false},{"pmid":"38272326","id":"PMC_38272326","title":"Reprimo (RPRM) mediates neuronal ferroptosis via CREB-Nrf2/SCD1 pathways in radiation-induced brain injury.","date":"2024","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38272326","citation_count":14,"is_preprint":false},{"pmid":"34576047","id":"PMC_34576047","title":"Stearoyl-CoA Desaturase (SCD) Induces Cardiac Dysfunction with Cardiac Lipid Overload and Angiotensin II AT1 Receptor Protein Up-Regulation.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34576047","citation_count":14,"is_preprint":false},{"pmid":"38492843","id":"PMC_38492843","title":"Scd1 and monounsaturated lipids are required for autophagy and survival of adipocytes.","date":"2024","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38492843","citation_count":13,"is_preprint":false},{"pmid":"36140684","id":"PMC_36140684","title":"Mechanism of SCD Participation in Lipid Droplet-Mediated Steroidogenesis in Goose Granulosa Cells.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36140684","citation_count":13,"is_preprint":false},{"pmid":"35401653","id":"PMC_35401653","title":"Outcome of Hydroxyurea Use in SCD and Evaluation of Patients' Perception and Experience in Nigeria.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35401653","citation_count":13,"is_preprint":false},{"pmid":"32858946","id":"PMC_32858946","title":"Metabolomic Analysis of SCD during Goose Follicular Development: Implications for Lipid Metabolism.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/32858946","citation_count":13,"is_preprint":false},{"pmid":"39832629","id":"PMC_39832629","title":"Huangqi-Danshen decoction alleviates renal fibrosis through targeting SCD1 to modulate cGAS/STING signaling.","date":"2025","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39832629","citation_count":12,"is_preprint":false},{"pmid":"33612070","id":"PMC_33612070","title":"NF-κB pathway play a role in SCD1 deficiency-induced ceramide de novo synthesis.","date":"2021","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33612070","citation_count":12,"is_preprint":false},{"pmid":"39405934","id":"PMC_39405934","title":"Artesunate-binding FABP5 promotes apoptosis in lung cancer cells via the PPARγ-SCD pathway.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39405934","citation_count":12,"is_preprint":false},{"pmid":"36712931","id":"PMC_36712931","title":"Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata.","date":"2022","source":"PNAS nexus","url":"https://pubmed.ncbi.nlm.nih.gov/36712931","citation_count":12,"is_preprint":false},{"pmid":"38244769","id":"PMC_38244769","title":"Active AKT2 stimulation of SREBP1/SCD1-mediated lipid metabolism boosts hepatosteatosis and cancer.","date":"2024","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38244769","citation_count":12,"is_preprint":false},{"pmid":"35246265","id":"PMC_35246265","title":"The Sickle Cell Disease Functional Assessment (SCD-FA) tool: a feasibility pilot study.","date":"2022","source":"Pilot and feasibility studies","url":"https://pubmed.ncbi.nlm.nih.gov/35246265","citation_count":12,"is_preprint":false},{"pmid":"39024737","id":"PMC_39024737","title":"Sickle cell disease in Indian tribal population: Findings of a multi-centre Indian SCD registry.","date":"2024","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39024737","citation_count":12,"is_preprint":false},{"pmid":"40080500","id":"PMC_40080500","title":"Piezo1 regulates colon stem cells to maintain epithelial homeostasis through SCD1-Wnt-β-catenin and programming fatty acid metabolism.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/40080500","citation_count":11,"is_preprint":false},{"pmid":"35122619","id":"PMC_35122619","title":"Blockage of NDUFB9-SCD1 pathway inhibits adipogenesis : Blockage of NDUFB9-SCD1 pathway inhibits adipogenesis.","date":"2022","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35122619","citation_count":11,"is_preprint":false},{"pmid":"37577386","id":"PMC_37577386","title":"A Scd1-mediated metabolic alteration participates in liver responses to low-dose bavachin.","date":"2023","source":"Journal of pharmaceutical analysis","url":"https://pubmed.ncbi.nlm.nih.gov/37577386","citation_count":11,"is_preprint":false},{"pmid":"35694255","id":"PMC_35694255","title":"Antidiabetic Effect of Rehmanniae Radix Based on Regulation of TRPV1 and SCD1.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35694255","citation_count":11,"is_preprint":false},{"pmid":"40473597","id":"PMC_40473597","title":"Circular RNA TFRC/SCD1 mRNA interaction regulates ferroptosis and metastasis in gastric cancer.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40473597","citation_count":10,"is_preprint":false},{"pmid":"39306652","id":"PMC_39306652","title":"GPR37 promotes colorectal cancer against ferroptosis by reprogramming lipid metabolism via p38-SCD1 axis.","date":"2024","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/39306652","citation_count":10,"is_preprint":false},{"pmid":"39409181","id":"PMC_39409181","title":"Leonurine Inhibits Hepatic Lipid Synthesis to Ameliorate NAFLD via the ADRA1a/AMPK/SCD1 Axis.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39409181","citation_count":10,"is_preprint":false},{"pmid":"40240331","id":"PMC_40240331","title":"C12ORF49 inhibits ferroptosis in hepatocellular carcinoma cells via reprogramming SREBP1/SCD1-mediated lipid metabolism.","date":"2025","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/40240331","citation_count":10,"is_preprint":false},{"pmid":"25816753","id":"PMC_25816753","title":"An SCD gene from the Mollusca and its upregulation in carotenoid-enriched scallops.","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/25816753","citation_count":10,"is_preprint":false},{"pmid":"37049884","id":"PMC_37049884","title":"Uncarboxylated Osteocalcin Decreases SCD1 by Activating AMPK to Alleviate Hepatocyte Lipid Accumulation.","date":"2023","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37049884","citation_count":10,"is_preprint":false},{"pmid":"37850770","id":"PMC_37850770","title":"Clinical and epidemiological features and therapeutic options of avascular necrosis in patients with sickle cell disease (SCD): a cross-sectional study.","date":"2023","source":"Acta bio-medica : Atenei Parmensis","url":"https://pubmed.ncbi.nlm.nih.gov/37850770","citation_count":10,"is_preprint":false},{"pmid":"37592151","id":"PMC_37592151","title":"METTL14 Suppresses Tumor Stemness and Metastasis of Colon Cancer Cells by Modulating m6A-Modified SCD1.","date":"2023","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/37592151","citation_count":10,"is_preprint":false},{"pmid":"39359808","id":"PMC_39359808","title":"CRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review.","date":"2024","source":"Annals of medicine and surgery (2012)","url":"https://pubmed.ncbi.nlm.nih.gov/39359808","citation_count":9,"is_preprint":false},{"pmid":"34171462","id":"PMC_34171462","title":"Polymorphisms rs55710213 and rs56334587 regulate SCD1 expression by modulating HNF4A binding.","date":"2021","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/34171462","citation_count":9,"is_preprint":false},{"pmid":"36507562","id":"PMC_36507562","title":"SCD1 Sustains Homeostasis of Bulge Niche via Maintaining Hemidesmosomes in Basal Keratinocytes.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36507562","citation_count":9,"is_preprint":false},{"pmid":"37897241","id":"PMC_37897241","title":"Reduced liver damage and fibrosis with combined SCD Probiotics and intermittent fasting in aged rat.","date":"2023","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37897241","citation_count":9,"is_preprint":false},{"pmid":"37543098","id":"PMC_37543098","title":"MicroRNA-199a-3p suppresses the invasion and metastasis of nasopharyngeal carcinoma through SCD1/PTEN/AKT signaling pathway.","date":"2023","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/37543098","citation_count":9,"is_preprint":false},{"pmid":"36471172","id":"PMC_36471172","title":"Upregulation of SCD1 by ErbB2 via LDHA promotes breast cancer cell migration and invasion.","date":"2022","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36471172","citation_count":9,"is_preprint":false},{"pmid":"33954906","id":"PMC_33954906","title":"Modulation of SCD1 activity in hepatocyte cell lines: evaluation of genomic stability and proliferation.","date":"2021","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33954906","citation_count":9,"is_preprint":false},{"pmid":"37031492","id":"PMC_37031492","title":"HOXB9 a miR-122-5p regulated gene, suppressed the anticancer effects of brusatol by upregulating SCD1 expression in melanoma.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37031492","citation_count":9,"is_preprint":false},{"pmid":"35528164","id":"PMC_35528164","title":"Molecular Hydrogen Inhibits Colorectal Cancer Growth via the AKT/SCD1 Signaling Pathway.","date":"2022","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/35528164","citation_count":9,"is_preprint":false},{"pmid":"36043959","id":"PMC_36043959","title":"Blood transfusion and iron overload in patients with Sickle Cell Disease (SCD): Personal experience and a short update of diabetes mellitus occurrence.","date":"2022","source":"Acta bio-medica : Atenei Parmensis","url":"https://pubmed.ncbi.nlm.nih.gov/36043959","citation_count":9,"is_preprint":false},{"pmid":"40007118","id":"PMC_40007118","title":"Enhanced fatty acid oxidation via SCD1 downregulation fuels cardiac reprogramming.","date":"2025","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/40007118","citation_count":8,"is_preprint":false},{"pmid":"39903889","id":"PMC_39903889","title":"LDHA- Mediated Histone Lactylation Promotes the Nonalcoholic Fatty Liver Disease Progression Through Targeting The METTL3/ YTHDF1/SCD1 m6A Axis.","date":"2024","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/39903889","citation_count":8,"is_preprint":false},{"pmid":"38637456","id":"PMC_38637456","title":"PPP2CA Inhibition Promotes Ferroptosis Sensitivity Through AMPK/SCD1 Pathway in Colorectal Cancer.","date":"2024","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38637456","citation_count":8,"is_preprint":false},{"pmid":"35887653","id":"PMC_35887653","title":"Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation.","date":"2022","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35887653","citation_count":8,"is_preprint":false},{"pmid":"33840688","id":"PMC_33840688","title":"High-fructose diet-induced hepatic expression of the Scd1 gene is associated with increased acetylation of histones H3 and H4 and the binding of ChREBP at the Scd1 promoter in rats.","date":"2021","source":"Biomedical research (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/33840688","citation_count":8,"is_preprint":false},{"pmid":"36843338","id":"PMC_36843338","title":"Desaturation of sebaceous-type saturated fatty acids through the SCD1 and the FADS2 pathways impacts lipid neosynthesis and inflammatory response in sebocytes in culture.","date":"2023","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/36843338","citation_count":8,"is_preprint":false},{"pmid":"38986822","id":"PMC_38986822","title":"Exosomes derived from periodontitis induce hepatic steatosis through the SCD-1/AMPK signaling pathway.","date":"2024","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38986822","citation_count":7,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53129,"output_tokens":9992,"usd":0.154634,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20825,"output_tokens":5949,"usd":0.126425,"stage2_stop_reason":"end_turn"},"total_usd":0.281059,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"SCD1 is the key rate-limiting enzyme that catalyzes the biosynthesis of monounsaturated fatty acids (MUFAs) from saturated fatty acids, playing a central role in fat cell metabolism and de novo lipogenesis. Its expression is regulated by dietary and hormonal signals.\",\n      \"method\": \"Review of biochemical and molecular studies on SCD gene family\",\n      \"journal\": \"Progress in lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — foundational enzymatic characterization replicated across multiple studies, established as rate-limiting desaturase activity\",\n      \"pmids\": [\"7480063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Oleate (an SCD1 product) specifically activates SREBP-1 nuclear accumulation and restores SREBP-1 expression and de novo lipogenesis in SCD1-deficient hepatocytes. SCD1 deficiency increases polyunsaturated fatty acid content, which in turn drives increased β-oxidation. These effects were demonstrated using Scd1-deficient mice and transgenic mice with liver-specific oleate or palmitoleate production.\",\n      \"method\": \"Scd1-deficient mice, transgenic mice (GLS5, GLS3), hepatocyte culture, SREBP-1 nuclear accumulation assay, gene expression analysis\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic mouse models with orthogonal methods, direct mechanistic link between SCD1 product oleate and SREBP-1 signaling established\",\n      \"pmids\": [\"28851735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SCD1 deficiency in skeletal muscle activates AMPK through an increase in AMP levels, while muscle-specific SCD1 overexpression decreases AMPK phosphorylation and the AMP/ATP ratio. AMPK changes caused by SCD1 modulation affect NAD+ levels and consequently SIRT1 activity and histone H3K9 acetylation/methylation status.\",\n      \"method\": \"SCD1 knockout mice, muscle-specific SCD1 overexpression mice, pharmacological SCD1 inhibition, measurement of AMP/ATP ratio, AMPK phosphorylation, NAD+ levels, SIRT1 activity, histone modification\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain- and loss-of-function in vivo models with multiple orthogonal metabolic readouts establishing SCD1→AMP/ATP→AMPK→SIRT1→histone acetylation axis\",\n      \"pmids\": [\"31241768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MITF is a lineage-restricted transcriptional activator of SCD (stearoyl-CoA desaturase) in melanoma. SCD is required for MITFHigh melanoma cell proliferation, and the MITF-SCD axis suppresses metastasis and inflammatory signaling. MITFLow cells are insensitive to SCD inhibition, demonstrating cell phenotype-dependent effects.\",\n      \"method\": \"Genetic SCD inhibition/knockdown in melanoma cells, MITF modulation, proliferation and invasion assays, in vivo metastasis models, transcriptional reporter assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacological loss-of-function with multiple orthogonal phenotypic readouts, lineage-restriction established through comparative cell models\",\n      \"pmids\": [\"31733993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Lactate uptake via MCT1 promotes ATP production in hepatocellular carcinoma cells, deactivating AMPK, leading to upregulation of SREBP1 and downstream SCD1, thereby enhancing production of anti-ferroptotic monounsaturated fatty acids and conferring resistance to ferroptosis inducers RSL3 and Erastin.\",\n      \"method\": \"MCT1 inhibition/genetic knockdown, AMPK activation/inhibition, SREBP1 and SCD1 modulation, ferroptosis assays in vitro and in vivo xenograft models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic and pharmacological interventions at each step of the pathway with in vitro and in vivo validation\",\n      \"pmids\": [\"33296645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FBW7 inhibits the expression of SCD1 via inhibiting the transcription factor NR4A1 (nuclear receptor subfamily 4 group A member 1), thereby promoting ferroptosis and apoptosis in pancreatic cancer cells.\",\n      \"method\": \"Gene expression profiling, targeted metabolite analysis, genetic FBW7 overexpression/knockdown, NR4A1 and SCD1 modulation, lipid peroxidation assays\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, mechanistic axis established by genetic manipulation but without direct promoter or binding studies for FBW7-NR4A1-SCD1\",\n      \"pmids\": [\"33271455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SCD1-derived PI(18:1/18:1) [1,2-dioleoyl-sn-glycero-3-phospho-(1'-myo-inositol)] is a signaling lipokine that inhibits p38 MAPK activation, counteracts the unfolded protein response (UPR) and ER-associated protein degradation, regulates autophagy, and inhibits apoptosis. SCD1 expression and PI(18:1/18:1) decrease during onset of cell death, repressing PP2A and enhancing stress signaling.\",\n      \"method\": \"Lipidomics, SCD1 inhibition/deficiency (Scd1-defective mice), exogenous PI(18:1/18:1) supplementation, p38 MAPK assays, UPR markers, PP2A activity assays, multiple cell lines and mouse tissues\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — identification of specific lipid product as signaling molecule, validated across multiple cell lines and mouse tissues with orthogonal biochemical assays\",\n      \"pmids\": [\"35624087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In X-linked adrenoleukodystrophy (ALD), SCD1 upregulation via chloroquine or LXR agonists shifts saturated very long-chain fatty acids (VLCFAs) toward monounsaturated VLCFAs, reducing ER stress and normalizing phospholipid profiles. Pharmacological SCD1 inhibition increases saturated VLCFAs, and CRISPR knockout of scd1 in zebrafish mimics the ALD motor phenotype.\",\n      \"method\": \"Drug screen in zebrafish ALD model, SCD1 pharmacological inhibition, CRISPR scd1 knockout in zebrafish, LXR agonist treatment in Abcd1-/y mice, ALD fibroblast ER stress assays, lipidomic analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic and pharmacological models across species with mechanistic readouts linking SCD1 activity to VLCFA saturation and ER stress\",\n      \"pmids\": [\"33690217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Loss of mitochondrial aconitase (ACO2) increases citrate flux toward fatty acid synthesis and upregulates SCD1, enhancing lipid desaturation to favor colorectal cancer growth. Pharmacological SCD inhibition selectively reduces tumor formation in ACO2-deficient CRC cells.\",\n      \"method\": \"ACO2 knockdown/overexpression, metabolomics, stable isotope tracing, SCD pharmacological inhibition, tumor formation assays\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — metabolic flux analysis combined with genetic and pharmacological perturbation in single lab\",\n      \"pmids\": [\"33676027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SCD1 deficiency in SCD1-null mice results in NF-κB pathway activation, increased phosphorylated NF-κB p65 nuclear translocation, upregulation of serine palmitoyltransferase 1 (SPT1), and elevated dihydroceramide synthesis in colorectal cancer cells. Supplemental oleate counteracts SCD1-inhibition-induced NF-κB activation, confirming that reduced MUFA levels are the key mediator.\",\n      \"method\": \"SCD1 inhibitor treatment, RNA-seq, NF-κB pathway analysis, ceramide measurement, oleate supplementation rescue experiments\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq combined with biochemical rescue assays in single lab establishing SCD1→MUFA→NF-κB→ceramide axis\",\n      \"pmids\": [\"33612070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SCD1 is a mechanoresponsive enzyme in hepatocellular carcinoma (HCC): high matrix stiffness increases SCD1 expression, which reprograms cellular lipid composition to enhance plasma membrane fluidity and promote HCC invasion and metastasis. Exogenous oleic acid (SCD1 product) mimics the effects of high matrix stiffness, rescuing invasive migration in cells cultured on soft substrates.\",\n      \"method\": \"Polyacrylamide gel mechanotune culture system, lipidomic analysis, SCD1 genetic knockdown/overexpression, oleic acid supplementation, plasma membrane fluidity assay, in vivo metastasis models\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanically tunable substrate culture, multiple orthogonal methods (lipidomics, genetic, pharmacological, oleic acid rescue) with in vivo validation\",\n      \"pmids\": [\"35358687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SCD1 inhibition in cancer cells reduces Wnt/β-catenin signaling, enhancing CCL4 production and promoting dendritic cell recruitment into tumors, which increases antitumor CD8+ T cell responses. In CD8+ T cells, SCD1 inhibition reduces ER stress, also enhancing CCL4 production. This dual effect synergizes with anti-PD-1 antibody therapy in mouse tumor models.\",\n      \"method\": \"SCD1 chemical inhibitor, SCD1 genetic knockout in mice, tumor models, CCL4 ELISA, DC and T cell functional assays, Wnt/β-catenin reporter assays\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological loss-of-function in multiple mouse tumor models, mechanistic dissection of two cell-type-specific pathways, single lab\",\n      \"pmids\": [\"35793868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SCD1 inhibition in CD8+ T cells reduces oleic acid and esterified cholesterol (generated by ACAT1) levels, directly enhancing IFN-γ production and cytotoxic activity. Addition of oleic acid or cholesteryl oleate reverses the enhanced T cell functions, establishing SCD1→oleic acid→ACAT1→esterified cholesterol as the mechanistic axis suppressing T cell effector function.\",\n      \"method\": \"SCD1 inhibitor treatment of CD8+ T cells in vitro, oleic acid/cholesteryl oleate supplementation rescue, tumor-infiltrating T cell lipid analysis in vivo, ACAT1 inhibitor experiments\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical rescue experiments establishing lipid intermediate pathway, in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"37879607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HBXIP transcriptionally induces SCD expression by coactivating the transcription factor ZNF263, resulting in accumulation of free fatty acids that suppress ferroptosis in HCC cells and reduce sensitivity to sorafenib.\",\n      \"method\": \"HBXIP overexpression/knockdown, ZNF263 coactivation assay, SCD expression analysis, MDA and GSH measurement, ferroptosis assays in vitro and in vivo\",\n      \"journal\": \"Acta pharmacologica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptional coactivation mechanism identified with functional ferroptosis readout, in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"36109580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Acidic tumor microenvironment activates the PI3K/AKT signaling pathway to increase SCD1 expression in liver cancer cells. Acidification also promotes direct binding between SCD1 and PPARα, an interaction that dissipates upon pH normalization, suggesting pH-dependent modulation of SCD1-PPARα interaction controls lipid accumulation.\",\n      \"method\": \"Acidic culture conditions, proteomic analysis, PI3K/AKT pathway inhibitors, SCD1-PPARα co-immunoprecipitation under different pH conditions\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP demonstrating SCD1-PPARα binding under acidic conditions, supported by pathway inhibitor experiments, single lab\",\n      \"pmids\": [\"35046108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SCD1 is an endoplasmic reticulum-membrane resident enzyme that is enriched in the distal small intestine and colon, and its intestinal-specific deletion (iKO mice) reduces not only intestinal lipids but also plasma triacylglycerols, diacylglycerols, cholesterol esters, and hepatic diacylglycerols. Intestinal SCD1 modulates hepatic de novo lipogenic gene expression via gut-liver crosstalk, potentially through production of the MUFA myristoleic acid.\",\n      \"method\": \"Intestine-specific SCD1 knockout (iKO) mice, comprehensive targeted lipidomics in intestine/liver/plasma, gene expression analysis of lipogenic genes\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific knockout with comprehensive lipidomic and gene expression profiling establishing gut-liver crosstalk\",\n      \"pmids\": [\"35718096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cardiac-specific SCD overexpression (4.9-fold) in transgenic mice causes cardiac hypertrophy and heart failure with reduced ejection fraction (25.7% vs. 54.3% controls). Tg-SCD hearts show increased cardiotoxic saturated lipids (palmitate, stearate), elevated p53, and upregulation of the angiotensin II AT1 receptor. In transfected HEK cells, SCD expression increases the number of cell-surface AT1 receptor binding sites.\",\n      \"method\": \"Cardiac-specific SCD transgenic mice, echocardiography, whole-genome gene expression profiling, lipid analysis, autoradiography, fluorescence spectroscopy of fluorescent protein-labeled AT1 receptor\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic model with multiple orthogonal readouts (echocardiography, lipidomics, transcriptomics, receptor binding), functional cardiac phenotype\",\n      \"pmids\": [\"34576047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SCD1 deficiency in keratinocytes impairs integrin α6β4 complex levels and hemidesmosome (HD) assembly, allowing aberrant activation of focal adhesion kinase (FAK) and PI3K, leading to keratinocyte differentiation/proliferation and disruption of the hair follicle bulge niche. PI3K inhibition in Scd1-/- mice normalizes the bulge, hair follicle stem cells, and hair growth. Oleic acid supplementation restores HDs and hair growth.\",\n      \"method\": \"Scd1 knockout mice (keratinocyte-specific), integrin complex analysis, hemidesmosome imaging, FAK/PI3K activity assays, PI3K inhibitor rescue, oleic acid supplementation rescue\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with dual pharmacological and lipid supplementation rescue, direct mechanistic link between SCD1 product (oleic acid), integrin complex, and hemidesmosome assembly\",\n      \"pmids\": [\"36507562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADAR1-mediated A-to-I RNA editing on the 3'UTR of SCD1 mRNA increases binding of the RNA-binding protein KHDRBS1, thereby augmenting SCD1 mRNA stability. Increased SCD1 facilitates lipid droplet formation, alleviates chemotherapy-induced ER stress, and enhances cancer cell self-renewal through increased β-catenin expression.\",\n      \"method\": \"Patient-derived organoid chemoresistant lines, WES + RNA-seq, A-to-I editing analysis, KHDRBS1 RIP assay, SCD1 mRNA stability assay, SCD1 pharmacological inhibition\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway from RNA editing to mRNA stability validated by RIP assay and multiple functional experiments in physiologically relevant patient-derived organoids\",\n      \"pmids\": [\"37208334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AKAP8L interacts with SCD1 mRNA and IGF2BP1 protein, regulating SCD1 mRNA stability in an IGF2BP1-dependent manner, thereby promoting gastric cancer cell stemness and chemoresistance to oxaliplatin.\",\n      \"method\": \"Mass spectrometry protein identification, co-immunoprecipitation of AKAP8L with IGF2BP1, RIP assay for AKAP8L-SCD1 mRNA interaction, AKAP8L overexpression/knockdown with SCD1 rescue\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP and co-IP demonstrating protein-mRNA and protein-protein interactions, functional rescue experiments, single lab\",\n      \"pmids\": [\"36522343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SCD1 positively regulates squalene epoxidase (SQLE) transcription by eliminating transcriptional inhibition by P53, thereby increasing cholesterol content. Elevated cholesterol regulated by SCD1 inhibits ferroptosis via the mTOR signaling pathway, promoting gastric cancer stem cell (GCSC) stemness.\",\n      \"method\": \"SCD1 knockdown, SQLE expression and promoter analysis, P53 binding assays, cholesterol measurement, mTOR pathway analysis, in vivo tumor stemness assays\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown with mechanistic promoter and pathway analysis, single lab\",\n      \"pmids\": [\"38972654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"METTL14-mediated m6A modification of SCD1 mRNA increases its recognition by the m6A reader YTHDF2, which destabilizes SCD1 mRNA and diminishes SCD1 expression, thereby suppressing Wnt/β-catenin signaling and colon cancer stemness and metastasis.\",\n      \"method\": \"METTL14 overexpression/knockdown, m6A methylation analysis of SCD1 mRNA, YTHDF2 RIP assay, mRNA stability assay, Wnt/β-catenin reporter assay\",\n      \"journal\": \"Molecular biotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — m6A modification and YTHDF2-SCD1 mRNA interaction established by RIP, functional rescue assays, single lab\",\n      \"pmids\": [\"37592151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HNF4A directly binds to key regulatory regions in the SCD1 locus. Knockdown of HNF4A significantly downregulates SCD1 expression. Two SNPs (rs55710213 and rs56334587) in intron 5 of SCD1 reside in a canonical HNF4A binding site; the GG haplotype disrupts HNF4A binding, reducing enhancer activity and SCD1 expression.\",\n      \"method\": \"HNF4A ChIP, HNF4A knockdown, luciferase reporter assay with SCD1 regulatory regions, allele-specific HNF4A binding analysis\",\n      \"journal\": \"Biochimica et biophysica acta. Gene regulatory mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for direct binding combined with reporter assays and knockdown, single lab\",\n      \"pmids\": [\"34171462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"High-fructose diet increases ChREBP binding to the Scd1 gene promoter and enhances histone H3 and H4 acetylation at this promoter, upregulating Scd1 expression in rat liver.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for ChREBP and histone acetylation at the Scd1 promoter, high-fructose diet rat model, gene expression and triglyceride measurement\",\n      \"journal\": \"Biomedical research (Tokyo, Japan)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct chromatin-level regulation of Scd1 promoter, single lab\",\n      \"pmids\": [\"33840688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Genetic ablation of SCD1 alone does not inhibit AKT-driven hepatic steatosis or AKT/Ras-induced hepatocarcinogenesis in mice. SCD2 is strongly upregulated to compensate in SCD1-null liver tumors. Simultaneous silencing of both SCD1 and SCD2 is required to inhibit growth of AKT/Ras cells in vitro.\",\n      \"method\": \"SCD1 knockout mice, hydrodynamic injection of AKT/Ras oncogenes, liver tumor analysis, SCD2 expression analysis, siRNA co-silencing of SCD1 and SCD2\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic in vivo model with clear negative result (SCD1 dispensable) and mechanistic explanation (SCD2 compensation), key finding for understanding SCD paralogs\",\n      \"pmids\": [\"24069385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Exercise increases endothelial SCD1 expression, which catalyzes production of oleic acid (OA) and palmitoleic acid (PA), mitigating NF-κB-mediated inflammatory responses. Endothelial-specific Scd1 deletion (Ldlr-/- Scd1EC-/- mice) on high-fat diet results in persistent VCAM1-positive endothelium; SCD1 overexpression via adenovirus mitigates ER stress and inflammatory biomarkers.\",\n      \"method\": \"Voluntary wheel running exercise, untargeted metabolomics, endothelial-specific Scd1 deletion in mice, adenoviral SCD1 overexpression, single-cell transcriptomics of aorta, inflammatory marker assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific genetic model combined with adenoviral rescue, metabolomics, and single-cell transcriptomics in vivo\",\n      \"pmids\": [\"38354249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SCD1 inhibition downregulates SLC7A11 expression via the AKT-GSK3β-NRF2 signaling axis, promoting ferroptosis and altering fatty acid metabolism. This mechanism was validated by transcriptomics, lipidomics, and kinase array analysis in preclinical KRASmut LUAD models.\",\n      \"method\": \"SCD1 inhibition, transcriptomics, lipidomics, kinase array, AKT-GSK3β-NRF2 pathway analysis, xenograft tumor models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-omic approach with pathway validation in preclinical models, single lab\",\n      \"pmids\": [\"40198901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SCD1 knockdown in cardiac fibroblasts activates PGC1α and PPARβ signaling, enhancing fatty acid oxidation (FAO)-related gene expression and mitochondrial biogenesis, thereby improving cardiac reprogramming efficiency (conversion of fibroblasts to induced cardiomyocytes).\",\n      \"method\": \"Scd1 knockdown, single-cell metabolic flux estimation, flux balance analysis, PGC1α/PPARβ pathway analysis, pharmacological SCD1 inhibition, mitochondrial biogenesis assays\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological manipulation with pathway analysis and metabolic modeling, single lab\",\n      \"pmids\": [\"40007118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"METTL16-mediated m6A modification of SCD1 mRNA increases its degradation via the m6A reader YTHDC2. METTL16 downregulation (due to DNMT1-mediated promoter hypermethylation) reduces m6A on SCD1 mRNA, increasing SCD1 expression and lipid metabolism, promoting papillary thyroid cancer progression.\",\n      \"method\": \"METTL16 gain/loss-of-function, m6A abundance measurement on SCD1 mRNA, YTHDC2 reader assay, RNA decay assay, SCD1 inhibitor A939572\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — m6A modification and YTHDC2 reader-dependent RNA decay established, functional consequences validated, single lab\",\n      \"pmids\": [\"38334797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IGF2BP3 regulates SCD mRNA m6A modifications via an IGF2BP3-METTL14 complex, enhancing SCD mRNA stability and thereby promoting lipid metabolism, proliferation, and metastasis in cervical cancer. RIP assay confirmed IGF2BP3 binding to SCD mRNA.\",\n      \"method\": \"RNA-seq target identification, RIP assay for IGF2BP3-SCD mRNA binding, methylated RNA immunoprecipitation (MeRIP), IGF2BP3 knockdown with SCD overexpression rescue, in vivo tumor model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP and MeRIP establish binding and m6A regulation of SCD, rescue experiments confirm functional axis, single lab\",\n      \"pmids\": [\"38355626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LDHA-mediated histone H3K18 lactylation is enriched on the METTL3 promoter, upregulating METTL3 expression. METTL3 increases m6A modification of SCD1 mRNA, recognized by YTHDF1 which stabilizes SCD1 mRNA, promoting lipid accumulation and NAFLD progression.\",\n      \"method\": \"IP and dual-luciferase reporter for H3K18lac on METTL3 promoter, METTL3/LDHA knockdown, m6A measurement of SCD1 mRNA, YTHDF1 RIP, RNA decay assay\",\n      \"journal\": \"Physiological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chromatin modification, m6A, and RBP-mRNA interaction chain experimentally established, single lab\",\n      \"pmids\": [\"39903889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SCD1 inhibition in colorectal cancer cells decreases MUFA levels, activates NF-κB pathway and de novo ceramide synthesis. A separate study (Liu et al.) shows TIGAR inhibition represses SCD1 expression in a ROS/AMPK-dependent manner, rendering colorectal cancer cells more sensitive to ferroptosis.\",\n      \"method\": \"SCD1 inhibitor, TIGAR knockdown, AMPK activation assay, ROS measurement, ferroptosis markers (MDA, GSH/GSSG, lipid peroxidation)\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological manipulation establishing TIGAR→ROS/AMPK→SCD1 axis, single lab\",\n      \"pmids\": [\"35271998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Nodal overexpression transcriptionally upregulates SCD1 via Smad2/3 pathway activation, inducing monounsaturated fatty acid synthesis and protecting colorectal cancer cells from ferroptosis. SCD1 inhibition at least partially abolishes the resistance of Nodal-overexpressing cells to RSL3-induced ferroptosis.\",\n      \"method\": \"Nodal overexpression/knockdown, Smad2/3 pathway analysis, SCD1 luciferase reporter, lipid peroxidation assays, ferroptosis induction, in vivo tumor models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptional mechanism via Smad2/3 to SCD1 promoter validated, functional ferroptosis rescue, single lab\",\n      \"pmids\": [\"37002201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SCD1 inhibition (via the RIFSP-2 peptide) limits MUFA biogenesis and decreases radiation-induced STING-mediated inflammation and pyroptosis. RIFSP-2 was identified as a direct binding target of SCD1 via a streptavidin-biotin pull-down system; lipidomic analysis confirmed that RIFSP-2 treatment restrains MUFA biogenesis.\",\n      \"method\": \"Streptavidin-biotin pull-down to identify SCD1 as RIFSP-2 target, lipidomics, STING pathway analysis, in vivo irradiation model\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding identification via pull-down, lipidomic functional validation, single lab\",\n      \"pmids\": [\"38582510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SULT2B1 directly interacts with SCD1 to facilitate lipid metabolism and promote colon cancer metastasis. Combined application of SCD1 inhibitor and SULT2B1 knockout showed a more robust inhibitory effect on lipid metabolism and metastasis than SULT2B1 knockout alone.\",\n      \"method\": \"Co-immunoprecipitation of SULT2B1 with SCD1, SULT2B1 knockout, SCD1 inhibitor CAY, lipid metabolism assays, orthotopic tumor model\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP demonstrating direct protein interaction, synergistic pharmacological/genetic evidence, single lab\",\n      \"pmids\": [\"38372484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Specific SCD1 inhibition in primary proximal tubular epithelial cells activates cGAS/STING signaling, and HDD treatment of renal fibrosis restores SCD1 expression while suppressing this pathway. This places SCD1 upstream of cGAS/STING signaling in renal tubular cells.\",\n      \"method\": \"SCD1 inhibitor A939572 in primary PTECs, cGAS/STING signaling markers, renal fibrosis mouse model, lipidomics\",\n      \"journal\": \"Journal of ethnopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological SCD1 inhibition directly activating cGAS/STING validated in primary cells and in vivo, single lab\",\n      \"pmids\": [\"39832629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Scd1 deficiency in adipocytes impairs autophagosome-lysosome fusion and lysosomal/autolysosomal acidification, leading to vacuole accumulation and cell death. Supplementation with monounsaturated fatty acids restores viability of Scd1-deficient adipocytes. In vivo, Scd1 deletion leads to loss of bone marrow adipocytes through autophagy-dependent cell death.\",\n      \"method\": \"Scd1 knockout adipocytes and mouse models, pharmacological SCD1 inhibition, autophagy flux assays, MUFA supplementation rescue, autophagosome formation inhibitor\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout in vitro and in vivo with pharmacological inhibition and MUFA rescue, directly establishing SCD1→MUFA→autophagosome-lysosome fusion\",\n      \"pmids\": [\"38492843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SCD1 in sebocytes catalyzes the Δ9 desaturation of palmitate (C16:0) to palmitoleate (C16:1n-7), while FADS2 catalyzes Δ6 desaturation to sapienate (C16:1n-10). Specific inhibition of SCD1 in SZ95 sebocytes enhances lipoinflammation induced by saturated fatty acids, indicating that SCD1-mediated desaturation normally limits inflammatory responses in sebaceous cells.\",\n      \"method\": \"Specific SCD1 and FADS2 inhibitors in SZ95 sebocytes, fatty acid profiling, IL-6/IL-8 cytokine measurement, lipid quantification\",\n      \"journal\": \"Experimental dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of SCD1 vs FADS2 desaturation pathways with functional inflammatory readout, single lab\",\n      \"pmids\": [\"36843338\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SCD1 (stearoyl-CoA desaturase 1) is an endoplasmic reticulum-resident enzyme that catalyzes the rate-limiting Δ9-desaturation of saturated fatty acids (principally palmitoyl- and stearoyl-CoA) to generate monounsaturated fatty acids (MUFAs), primarily palmitoleate and oleate; these MUFAs in turn serve as structural components of membrane phospholipids, substrates for triglyceride synthesis, and signaling lipids (e.g., PI(18:1/18:1)) that suppress p38/UPR/apoptosis stress pathways, modulate AMPK/SIRT1 activity and histone acetylation through effects on AMP/ATP ratios, activate SREBP-1 nuclear accumulation to sustain lipogenesis, maintain hemidesmosome integrity via integrin α6β4, regulate plasma membrane fluidity to control cell invasion, and protect against ferroptosis by limiting polyunsaturated fatty acid availability for lipid peroxidation; its transcriptional regulation involves MITF, HNF4A, ChREBP (via histone acetylation), HBXIP-ZNF263, and Smad2/3, while its mRNA stability is controlled post-transcriptionally by ADAR1-mediated RNA editing recruiting KHDRBS1 and by multiple m6A writer-reader systems (METTL3-YTHDF1, METTL14-YTHDF2, METTL16-YTHDC2).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SCD (stearoyl-CoA desaturase 1) is an endoplasmic reticulum-resident enzyme that catalyzes the rate-limiting Δ9-desaturation of saturated fatty acids into monounsaturated fatty acids (MUFAs), a reaction central to de novo lipogenesis and fat cell metabolism [#0, #15]. Its principal products—oleate and palmitoleate—act not only as building blocks for membrane and storage lipids but as signaling intermediates: oleate drives SREBP-1 nuclear accumulation to sustain lipogenesis [#1], modulates the AMP/ATP ratio to control AMPK→SIRT1→histone acetylation [#2], and the specific phospholipid PI(18:1/18:1) suppresses p38 MAPK, the unfolded protein response, and apoptosis while regulating autophagy [#6]. By converting saturated very-long-chain and palmitoyl/stearoyl species to MUFAs, SCD limits ER stress, NF-κB-driven inflammation, and ceramide accumulation across endothelium, sebocytes, intestine, and disease models [#7, #9, #25, #37], and supports autophagosome–lysosome fusion required for adipocyte viability [#36]. A recurrent theme is SCD's protection against ferroptosis: by enriching cells in anti-peroxidative MUFAs and influencing cholesterol and SLC7A11 metabolism, it confers resistance to ferroptosis inducers and chemotherapy in multiple cancers [#4, #13, #20, #26, #32]. SCD is heavily controlled at multiple regulatory layers—transcriptionally by MITF, HNF4A, ChREBP, HBXIP-ZNF263, and Nodal/Smad2/3 [#3, #22, #23, #13, #32], and post-transcriptionally through ADAR1-KHDRBS1 RNA editing and several m6A writer–reader systems (METTL14-YTHDF2, METTL16-YTHDC2, METTL3-YTHDF1) that tune SCD mRNA stability [#18, #21, #28, #30]. In cancer SCD frequently promotes invasion, stemness, and immune evasion—membrane-fluidity-dependent invasion under matrix stiffness [#10], suppression of CD8+ T cell effector function via oleate/ACAT1 [#12], and stem-cell self-renewal [#18]—though its dispensability can be masked by paralog SCD2 compensation [#24]. Pharmacological SCD1 inhibition is contextually linked to motor phenotypes in adrenoleukodystrophy and cardiac, renal, and inflammatory disease models [#7, #16, #35].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established SCD1 as the rate-limiting desaturase converting saturated fatty acids to MUFAs, defining its core enzymatic role in lipogenesis and fat metabolism.\",\n      \"evidence\": \"Review synthesizing biochemical and molecular studies of the SCD gene family\",\n      \"pmids\": [\"7480063\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not resolve isoform/paralog-specific substrate preferences in vivo\", \"No structural mechanism of catalysis provided\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed SCD1 is genetically dispensable for AKT/Ras-driven hepatocarcinogenesis because paralog SCD2 compensates, defining when targeting SCD1 alone fails.\",\n      \"evidence\": \"SCD1 knockout mice with AKT/Ras hydrodynamic injection plus siRNA co-silencing of SCD1/SCD2\",\n      \"pmids\": [\"24069385\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue/tumor contexts where SCD2 compensation does not occur not delineated\", \"No combined pharmacological dual-inhibitor validation in vivo\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified the SCD1 product oleate as the signal that restores SREBP-1 nuclear accumulation and lipogenesis, linking enzyme output to a transcriptional feed-forward loop.\",\n      \"evidence\": \"Scd1-deficient and liver-specific oleate/palmitoleate transgenic mice with hepatocyte SREBP-1 assays\",\n      \"pmids\": [\"28851735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which oleate promotes SREBP-1 processing unresolved\", \"Relative contribution of oleate vs palmitoleate not separated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected SCD1 activity to cellular energy state, showing it controls AMP/ATP ratio, AMPK, NAD+/SIRT1, and histone acetylation in muscle.\",\n      \"evidence\": \"SCD1 knockout and muscle-specific overexpression mice with metabolic and epigenetic readouts\",\n      \"pmids\": [\"31241768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical link between MUFA levels and AMP generation not defined\", \"Generality beyond skeletal muscle unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a lineage-restricted MITF-SCD transcriptional axis required for MITFHigh melanoma proliferation, establishing context-dependent SCD dependency.\",\n      \"evidence\": \"Genetic/pharmacological SCD perturbation with MITF modulation, proliferation/invasion and in vivo metastasis assays\",\n      \"pmids\": [\"31733993\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct MITF binding to SCD promoter not detailed\", \"Mechanism of MITFLow insensitivity unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified the specific SCD1-derived lipokine PI(18:1/18:1) as a suppressor of p38/UPR/apoptosis and regulator of autophagy and PP2A, elevating SCD1 from metabolic enzyme to signaling hub.\",\n      \"evidence\": \"Lipidomics, Scd1-defective mice, exogenous PI(18:1/18:1) supplementation, p38/UPR/PP2A assays across cell lines and tissues\",\n      \"pmids\": [\"35624087\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular target/receptor of PI(18:1/18:1) not identified\", \"How PI(18:1/18:1) represses PP2A mechanistically unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated that SCD1-mediated shift from saturated to monounsaturated VLCFAs reduces ER stress, linking SCD1 to adrenoleukodystrophy pathology.\",\n      \"evidence\": \"Zebrafish ALD drug screen and CRISPR scd1 knockout, LXR agonists in Abcd1-/y mice, ALD fibroblast ER stress and lipidomics\",\n      \"pmids\": [\"33690217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SCD1 modulation is therapeutic in human ALD not established\", \"Mechanism of VLCFA recognition by SCD1 not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked SCD1 to multiple upstream metabolic and transcriptional regulators (ACO2 citrate flux, HNF4A binding, ChREBP/histone acetylation), building the input map for SCD1 expression.\",\n      \"evidence\": \"ACO2 perturbation with isotope tracing; HNF4A ChIP/knockdown/reporter with SNP analysis; ChREBP/histone ChIP in fructose-fed rats\",\n      \"pmids\": [\"33676027\", \"34171462\", \"33840688\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cross-tissue generality of each regulatory input not tested\", \"Interplay among these regulators on the SCD1 locus unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established SCD1 as a downstream effector protecting cancer cells from ferroptosis via MUFA production, regulated by lactate/MCT1-AMPK-SREBP1 and FBW7-NR4A1 axes.\",\n      \"evidence\": \"MCT1 and FBW7/NR4A1 perturbation, AMPK/SREBP1 modulation, ferroptosis assays in vitro and in xenografts\",\n      \"pmids\": [\"33296645\", \"33271455\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter/binding evidence for FBW7-NR4A1-SCD1 lacking\", \"Quantitative contribution of SCD1 vs other anti-ferroptotic factors unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed SCD1 is mechanoresponsive and promotes invasion by remodeling membrane fluidity, while also reprogramming the antitumor immune microenvironment.\",\n      \"evidence\": \"Mechanotunable substrate culture, lipidomics, genetic/pharmacological SCD1 manipulation with oleic acid rescue, plus tumor immune models (CCL4, DC/CD8 assays, anti-PD-1)\",\n      \"pmids\": [\"35358687\", \"35793868\", \"37879607\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism converting membrane fluidity to invasion signaling not defined\", \"Direct sensor coupling matrix stiffness to SCD1 transcription unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended SCD1's protective MUFA function to tissue physiology—hemidesmosome/integrin α6β4 integrity in keratinocytes, cardiac lipotoxicity on overexpression, and gut-liver lipid crosstalk.\",\n      \"evidence\": \"Keratinocyte-specific Scd1 KO with PI3K-inhibitor and oleate rescue; cardiac-specific SCD transgenic mice; intestine-specific SCD1 KO with lipidomics\",\n      \"pmids\": [\"36507562\", \"34576047\", \"35718096\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking MUFA supply to integrin complex stability unresolved\", \"AT1 receptor upregulation mechanism in cardiac overexpression not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified protein-level and microenvironmental regulators of SCD1 (HBXIP-ZNF263 transcription, pH-dependent SCD1-PPARα binding), expanding its regulatory inputs.\",\n      \"evidence\": \"HBXIP/ZNF263 coactivation assays with ferroptosis readouts; proteomics and pH-dependent SCD1-PPARα co-IP with PI3K/AKT inhibitors\",\n      \"pmids\": [\"36109580\", \"35046108\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of SCD1-PPARα interaction not mechanistically resolved\", \"Single co-IP basis for the SCD1-PPARα interaction\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined post-transcriptional control of SCD1 by ADAR1 A-to-I editing recruiting KHDRBS1, and AKAP8L/IGF2BP1, that stabilize SCD1 mRNA to drive cancer stemness and chemoresistance.\",\n      \"evidence\": \"Patient-derived organoids, RNA editing and RIP assays, mRNA stability assays, co-IP, with SCD1 inhibition\",\n      \"pmids\": [\"37208334\", \"36522343\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether editing and m6A pathways converge on the same transcripts unknown\", \"AKAP8L-IGF2BP1-SCD1 axis from single lab without reciprocal validation\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established m6A writer-reader control of SCD1 mRNA stability (METTL14-YTHDF2) and SCD1's downstream control of SQLE/cholesterol and Wnt/β-catenin in cancer stemness and ferroptosis.\",\n      \"evidence\": \"MeRIP/RIP, mRNA decay assays, SQLE promoter and P53 binding analysis, Nodal/Smad2/3 reporter, ferroptosis assays\",\n      \"pmids\": [\"37592151\", \"38972654\", \"37002201\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type specificity of opposing m6A reader outcomes unresolved\", \"Direct vs indirect SCD1 control of SQLE transcription not fully separated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Broadened SCD1's physiological roles—endothelial anti-inflammatory protection during exercise, adipocyte autophagy/lysosomal function, and cardiac reprogramming—through MUFA-dependent mechanisms.\",\n      \"evidence\": \"Endothelial-specific Scd1 KO with adenoviral rescue and single-cell transcriptomics; Scd1 KO adipocytes with MUFA rescue and autophagy flux; cardiac fibroblast Scd1 knockdown with metabolic flux modeling\",\n      \"pmids\": [\"38354249\", \"38492843\", \"40007118\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which MUFAs support lysosomal acidification unresolved\", \"Generalizability of endothelial findings beyond Ldlr-/- model untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected SCD1 inhibition to innate immune and ferroptotic stress pathways (cGAS/STING, AKT-GSK3β-NRF2-SLC7A11) and identified direct SCD1-binding modulators (RIFSP-2, SULT2B1).\",\n      \"evidence\": \"SCD1 inhibitors with transcriptomics/lipidomics/kinase arrays, cGAS/STING markers, biotin pull-down and co-IP, in vivo tumor/fibrosis/irradiation models\",\n      \"pmids\": [\"40198901\", \"39832629\", \"38582510\", \"38372484\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular events linking MUFA loss to STING activation not defined\", \"SCD1-SULT2B1 interaction from single co-IP without structural detail\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolved additional m6A regulatory systems controlling SCD1 mRNA (METTL16-YTHDC2, METTL3-YTHDF1, IGF2BP3-METTL14), showing layered and tissue-specific tuning of SCD1 in cancer and NAFLD.\",\n      \"evidence\": \"Gain/loss-of-function of m6A enzymes, m6A abundance and reader RIP assays, RNA decay assays, H3K18lac/promoter analysis, in vivo models\",\n      \"pmids\": [\"38334797\", \"39903889\", \"38355626\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Hierarchy and competition among the multiple m6A reader systems on SCD1 unknown\", \"Each axis established in a single tumor context\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse upstream regulators and the distinct MUFA-derived signals (PI(18:1/18:1), oleate, palmitoleate) are integrated to produce context-specific outcomes—ferroptosis resistance, invasion, immune suppression, or tissue protection—remains unresolved.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model coupling specific lipid products to specific downstream effectors\", \"Structural basis of SCD1 desaturation and substrate selectivity not addressed in corpus\", \"Predictors of SCD1 dependency vs SCD2 compensation across tissues undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 37]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 37]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 15]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 6, 32, 36]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [18, 21, 28, 30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PPARA\", \"SULT2B1\", \"KHDRBS1\", \"IGF2BP1\", \"AKAP8L\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}